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General introduction 

General introduction 
Respiratory diseases are a major cause of morbidity in preschool children. Confronted with young children with respiratory symptoms the physician 
faces many uncertainties regarding the diagnosis, treatment and prognosis, 
namely: 
• labelling of chronic and recurrent respiratory symptoms and defining 'asthma'; 
• the natural course of respiratory symptoms and the relation with future asthma; 
the effectivity and side-effects of anti-asthma treatment, for both relief and pro-
phylaxis; 
• the feasibility of and compliance with prophylactic inhalation therapy. 
In studying effectivity of anti-asthma drugs, the investigator has additional prob-
lems: 
• symptoms as outcome measure; 
• the difficulty of conducting clinical trials, finding the appropriate setting and 
considering the ethical aspects of research in young children. 
In this chapter, the background of these uncertainties for physicians and investi-
gators will be explored further. The place of sodium cromoglycate in prophylactic 
therapy will be discussed in detail because it is the main focus of the studies in 
this thesis. The results of this research will be presented in the following chapters 
together with results of studies on preschool asthma in general practice and on 
the feasibility of and adherence to maintenance inhalation therapy. 
labelling chronic and recurrent respiratory 
symptoms in young children 
Presentation of asthma symptoms in young children varies from acute wheezy 
episodes, often associated with viral infections, to recurrent daily symptoms. 
These symptoms can be labelled in different ways; i.e. asthma, recurrent or per-
sistent wheezing. These terms are ill definedl since a suitable method of lung 
function measurement to distinguish between the diagnoses is lacking. The de-
bate on the term "asthma" is ongoing: without qualification or definition the term 
is too imprecise. 2 Data reporting the prevalence of 'asthma' and 'wheezing' in 
children under the age of four years to range between 10% and 20% 3.4, have to 
be considered in this perspective; the variation could be the result of different 
definitions. It has been suggested to use the term "asthma" for children with 
measurable reversible airway obstruction, but this raises difficulties for preschool 
children in whom even measurement of peak flow is not possible and findings of 
physical examination are not precise. In this age group we considered that the 
diagnosis of asthma should be applied to children whose symptoms and burden 
of disease warrant specific treatment. This means that, in our studies, the sepa-
rate terms 'asthma' and 'wheezing' are combined under the label 'asthma' .. ln this 
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line of thought, a positive response to a therapeutic trial of a ~2-agonist and/or 
inhaled steroid therapy may help to identify the disease,' whereby this judgement 
is solely based on subjectively measured symptom relief. 
Natural course of respiratory symptoms related 
to future asthma 
It is known that some of the children with symptoms suggestive of asthma under 
the age of four years will have asthma in the future, because most of them out-
grow the symptoms.'·B So far, it has not been possible to detect with any cer-
tainty the individual prognosis of asthmatic infants with recurrent wheeze. The 
prime limiting factor in measuring outcome is the inability to verify the disorder 
itself in an objective manner.4 There is evidence that acute viral wheezy episodes 
in the very young represent a type of airway disease clinically distinct from atopic 
asthma 6 .?' Martinez and colleagues measured lung function by the chest com-
pression technique in 125 one-year-olds and showed that lung function before 
the first wheezy episode may predict wheeze during the first 2-3 years but not at 
six years of age6 They defined two types of wheezing infants: a group with tran-
sient wheeze associated with diminished airway function at birth and not having 
increased risks of asthma or allergies in later life, and another type with wheezing 
episodes related to a predisposition to asthma. It is not clear, however, how 
these two types of children can be distinguished by different clinical patterns 
prospectively, and whether or not they require different therapeutic approaches, 
such as relief therapy on demand or anti-inflammatory prophylaxis. 
Effectivity of prophylactic anti-asthma treatment 
The possible existence of different types of wheeze in young children, requiring 
different therapies, may explain the variable findings in trials with asthma medica-
tion in preschool children. 1O·12 
Until the revision of the British Thoracic Society guidelines for asthma in 1997, 
inhalation therapy with sodium cromoglycate was recommended as first-choice 
prophylactic treatment for moderate asthma in young childrens .13 From 1997 
inhaled steroids and sodium cromoglycate occupied an equal place in the rec-
ommendations. 5 The most recent guidelines state that the balance of risk and 
benefit may be negative for treatment of mild cases with inhaled steroids, be-
cause of the unknown long-term side-effects in early childhood. For such chil-
dren, cromoglycate should still be considered as first-choice preventive treat-
ment. Recent United States guidelines continue to recommend cromoglycate as 
first choice in infants and young children 14; this despite the fact that data on the 
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effectivity of sodium cromoglycate in preschool children with mild and moderate 
asthma is lacking. 
Sodium cromoglycate 
Roger Altounyan was born in 1922 and he was first diagnosed with allergic 
asthma when he was a medical student. 15 He noted that one compound derived 
from khellin, a plant extract, appeared to decrease the antigen response in sensi-
tised guinea pig tissue. This observation convinced him that it would be possible 
to develop a drug that treated asthma by blocking the release of mast cell media-
tors rather than by simply antagonising their effects. Between 1957 and 1964 he 
tested various compounds on himself for their anti-allergic properties. After test-
ing hundreds of derivatives of khellin he identified one compound, disodium 
cromoglycate, that was consistently able to attenuate his allergic response.16 In a 
first paper (1964) a patient, Altounyan himself, had a fall in FEV, after antigen 
challenge, and inhaled cromoglycate provided significant protection.17 The next 
step was a clinical trial conducted by his friend Dr Jack HowelL" A group of 10 
adults was studied using a double-blind, crossover design. There was a two-week 
run-in period and two weeks of placebo, preceded or followed by two weeks of 
nebulised cromoglycate. The outcome variable was the clinical judgement by 
Howell and he judged that all 10 subjects were better during the treatment pe-
riod with the active drug than with placebo. Many trials have since been under-
taken, and the overall conclusion was that inhaled SCG is an effective treatment 
in 70% of asthmatic patients. In the history of cromoglycate two important trials 
were published in 1972: in school-age children" and in adults.'" Cromoglycate 
became a major therapeutic agent in the treatment of asthma and Altounyan is 
still honoured by an annual lecture for his discovery. 
Sodium cromoglycate was first introduced as an inhaled treatment for bronchial 
asthma in the late 1960s. Initially it was presented as 20 mg sodium cromogly-
cate combined with 0.1 mg isoprenaline sulphate in a capsule which was inhaled 
using a spinhaler. Shortly afterwards cromoglycate without isoprenaline was in-
troduced and newer formulations were manufactured; e.g. an aqueous solution 
for nebulisation and metered dose inhalers. The most commonly used form at 
present is the metered dose inhaler delivering 5 mg cromoglycate per actuation. 
In addition to the effect on mast cells, sodium cromoglycate has inhibitory ac-
tions on macro phages, eosinophils, monocytes and platelets, all important com-
ponents in the inflammatory response of asthma. Its mechanism of action is not 
yet fully understood. 21 Cromoglycate has no acute bronchodilator effect and 
must be used continuously to control asthma inflammation in a prophylactic way. 
In addition to long-term prophylaxis, cromoglycate can be used as a prophylactic 
immediately before exposure to bronchoconstricting stimuli, like exercise." 
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Distribution of asthma prescriptions in 1·4·year old children in general practice 
Recent trends in anti-asthma drug prescriptions 
Already before the change in guidelines inhaled steroids became more important 
and are regarded today as first-line prophylactic anti-inflammatory treatment.s,23 
There is also a trend in favour of using inhaled steroids in mild asthma in children, 
presumably due to their higher potency,23 In the UK 52%, of 17000 children 
with asthma from 398 general practices were prescribed preventive treatments in 
1990" ; 17% were prescribed cromoglycate (a declining number) and 39% in-
haled steroids (a rising number), In a survey by Anderson and colleagues that 
reported the use of anti-asthmatic drugs in 1978 and 1991, the proportion of 
wheezy children increased from 26% to 57"/0," The use of inhaled steroids had 
increased from 2% to 17%, but changes in the use of cromoglycate were not 
specified, In the Netherlands the number of prescriptions for cromoglycate has 
decreased during the 1990s, both from general practitioners and specialists, and 
the number of consultations for 'asthma' has increased," Figure 1 shows the dis-
tribution of drugs prescribed for asthma in children 1-4 years, by Dutch general 
practitioners in 1993-1997," 
A notable finding is the decline in the number of prescriptions for sodium cro-
moglycate at a time when the drug was still recommended as first choice pro-
phylactic treatment in children with moderate asthma, both in the UKs,24 and in 
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the Netherlands" and when the risk of overtreatment with inhaled steroids in 
young children with mild asthma had been noticed.2~30 The issues of the efficacy 
and safety of long-term steroid treatment in preschool children are still unsolved 
due to insufficient knowledge on the optimal dose, lung deposition and delivery 
from the available devices." Moreover, the majority of studies evaluating the risk 
of systemic side-effects have addressed children older than five years. A potential 
role for sodium cromoglycate in the treatment of moderate asthma in young 
children still exists. A retrospective study even suggested that cromoglycate may 
improve the long-term prognosis of childhood asthma.31 
Achieving control of asthma in young children remains difficult, as reflected by 
increasing morbidity on the one hand, and the increasing use of anti-inflamma-
tory therapies on the other. 3,24,32,33 This, and the uncertainties about the effective-
ness of sodium cromoglycate and about long-term side-effects of inhaled steroids, 
prompted us to investigate and review the effects of sodium cromoglycate in 
young children with asthma. 
Feasibility of and compliance with inhalation 
therapy 
Inhalation therapy is the preferable way to administer anti-asthma medication to 
children,' because it enables the drug to act directly and selectively. The availabil-
ity of spacer devices with facemasks has extended the applicability of metered 
dose inhalers to preschool children and their use is more simple than the use of 
nebulizers. Spacer devices and nebulizers have shown to be equally effective. 34,35 
Various spacer devices with facemasks are available for symptomatic and pro-
phylactic treatment. Little is known, however, about the feasibility in terms of 
parent/patient adherence and compliance in children aged 1-4 years in the home 
situation. Compliance with inhaled asthma treatment in children and adults is 
generally poor. The extent to which asthma patients of all ages follow prescribed 
treatment plans is reported to range from 30% to 70%." Non-adherence may 
have considerable consequences for morbidity, clinical trial outcomes and costs 
of treatment. 
Conducting clinical trials in an appropriate 
setting 
Clinical trials of effectivity of asthma drugs are complicated in young children, 
mainly because of the uncertainties mentioned previously and because of the 
ethical aspects of research in this age group. In the Netherlands, most children 
with asthma are treated by their general practitioner.",37 Only complicated cases 
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or children with severe asthma are referred to and treated by a specialist. Since 
sodium cromoglycate is recommended for children with moderate asthma, the 
most appropriate setting to investigate the effectivity of cromoglycate is in the 
home situation, with children enrolled from general practices. The biggest chal-
lenge of conducting a randomised controlled trial in general practice is the en-
rolment of participating physicians and patients.'·5" Being mainly a data collector, 
the general practitioner may be daunted by time-consuming and tedious extra 
work of instructing the patients, registering baseline and follow-up data, etc. 
Therefore, trials in general practice are at risk of failure due to unsuccessful data 
collection and require specific methodology. 
Symptoms as outcome measure 
This item is closely related to the difficulty of diagnosing asthma in young chil-
dren. Again, the most important limiting factor in measuring outcome is the in-
ability to measure asthma itself.' In young children, symptom assessment is the 
basis for most clinical treatment schemes, although symptoms are poorly defined 
and scoring systems have not been validated against objective measures of air-
flow obstruction or disability. Until a method of lung function assessment suitable 
for home use in this age group is available, overall measurement of symptom 
severity should include the frequency, duration and magnitude of episodes and 
interval symptoms,38 Validation using objective measures is required, 
This thesis 
More specifically, this thesis aims to clarify a number of the uncertainties de-
scribed above, These are: 
• Is it feasible for young children (and their parents) to inhale a prophylactic drug 
for several months with a spacer device? 
• What are the effects of inhalation therapy of sodium cromoglycate, compared 
to placebo, on asthma symptoms? 
• Is it possible to conduct a clinical trial in general practice in which researchers 
are responsible for enrolment, inclusion, randomisation and follow-up? 
• Is it possible to find determinants of children who still use inhaled prophylactic 
treatment eight months after finishing the trial? 
• What are the reported effects of inhaled sodium cromoglycate in children, in 
published randomised placebo controlled trials? 
The research questions are addressed in the following chapters, Chapter two 
presents a study investigating whether, and how, children with asthma can be 
identified in the computerised records of general practitioners in the Netherlands, 
Subsequently, a randomised placebo-controlled trial of sodium cromoglycate in 
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218 children with moderate asthma, aged 1-4 years, in the home situation was 
conducted. Chapter three presents the findings of this trial, and in chapter four 
the practical aspects involved in patient recruitment, randomisation and follow-
up of such a clinical trial in primary care are discussed. The feasibility of 
inhalation therapy with a spacer device is further investigated in chapter five in 
which willingness to participate in the trial, loss of participants during the trial and 
compliance are reported. In chapter six the predictors for use of prophylactic 
inhalation therapy eight months after finishing the trial in the children that partici-
pated are addressed. In chapter seven the findings of all published randomised 
placebo-controlled trials on prophylactic treatment with sodium cromoglycate in 
children with asthma are assessed and interpreted in a systematic review. The 
main conclusions of these studies are discussed in chapter eight in which sugges-
tions for future research are also made. The thesis ends with a summary in both 
English and Dutch. 
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Preschool children with asthma: are they known to their CPs? 
Introduction 
Since Speight highlighted the underdiagnosis and undertreatment of childhood 
asthma more than 15 years ago,' the subject has been of increasing interest to 
researchers, clinicians and general practitioners. This is reflected in the publica-
tion of various consensus reports during the last few years. 2-S Consequently, we 
would expect more children with asthma-like symptoms to be known to their 
GPs. 
The prevalence of asthma in 0-4 year olds is high; rates varies from 5% to 31 % 
according to the definition of asthma and methods of identifying cases used. 
Several reports have recommended appropriate care2-S and some authors have 
argued that this may improve long-term prognosis."? In a general practice audit 
by Levy only one third of asthmatic children had their illness diagnosed before 
the age of four, despite most having presented respiratory symptoms by this 
age.' By studying GPs' medical records of children, Neville found that 32% were 
potentially asthmatic9 No attempt was made, however, to validate these findings 
by interviewing parents. Strachan'o reviewed general practice records of 369 
children at seven years of age: 31 % had some record of wheeze. After compar-
ing the records with data from parental questionnaires of 174 of these children, 
the author concluded that parental recall of early episodes is incomplete and 
biased by the severity and persistence of the symptoms of the child. 
In the Netherlands every patient is registered with a general practitioner who acts 
as gatekeeper to secondary care. This offers a comprehensive sampling base for 
research into such a prevalent disorder as asthma. We compared GPs medical 
records of children with parental questionnaires to answer the following ques-
tion: are preschool children with asthma known to their G P? 
Methods 
In autumn 1992 parents of all 464 preschool children (1-4 years) of five general 
practices affiliated with the Department of General Practice of Erasmus Univer-
sity, received a mail questionnaire through their own GP. Two weeks later a re-
minder was sent to non-responders. 
As there is no suitable and well-validated questionnaire for assessing asthma in 
this age group," we constructed a questionnaire for this objective, adopting vali-
dated questions from previously developed questionnaires."-14 The questionnaire 
contained items about asthma symptoms (e.g. wheezing, dyspnoea), past and 
present asthma medication and morbidity experienced by the child. Based on 
questionnaire answers, the children were classified as having no, mild, moderate 
or severe asthma (Table 1). Classification was based on recurrent airway symp-
15 
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toms and use of specific asthma medication.2-5 Peak-flow measurements are not 
possible in most preschool children. Jones et al. showed that asthma symptoms 
are closely related to results of lung function tests in children over five years. 12 
We examined general practitioners' records of these children, checking them for 
asthma symptoms, specific asthma medication, and asthma-related diagnoses 
(asthma, acute bronchitis, chronic non-specific respiratory disease) since birth. 
The two people who studied the files were unaware of the answers in the paren-
tal questionnaire. 
Finally, asthma ,severity, as based on questionnaire answers, was compared to 
asthma symptoms, specific asthma medication and asthma-like diagnoses as 
found in the general practitioners' records. Data were analysed with SPSS-PC. 
Differences between responders and non-responders were tested by means of a 
x2-test (p<.05). 
Table 1 
Classification of asthma severity according to questionnaire answers 
NO ASTHMA 
. no respiratory symptoms and no medication 
MILD ASTHMA 
dyspnoea at least twice in past 12 months 
wheezing 4 to 12 times in past 12 months 
present weekly use bronchodilators during <6 weeks 
present daily use of deptropine during <6 weeks or deptropine use in past 12 months 
jf doctor ever said to parents their child has asthma 
if parents think their child has asthma now 
MODERATE ASTHMA 
wheezing >12 times in the past 12 months 
2 out of 3 of following questions answered lyesl:8 
- Wheezy or asthmatic condition ;:0:1 per week? 
- Hampered in daily activities (feeding, play, going to school or creche)? 
- Wake up from coughing or wheezing during nighttime? 
present use of sodium-cromoglycate or ketotifen 
present use of deptropine during ;:0:6 weeks 
present daily use of bronchodilators 
present weekly or monthly use of bronchodilators during;::"6 weeks 
use of corticosteroids during <3 weeks in past 12 months 
SEVERE ASTHMA 
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all 3 following questions answered lyesl:8 
- Wheezy or asthmatic condition ;::..1 per week? 
- Hampered in daily activities (feeding, play, going to school or creche)? 
- Wake up from coughing or wheezing during nighttime? 
use of corticosteroids during ;::..3 weeks in past 12 months 
present use of corticosteroids 
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Results 
The final response to the questionnaire was 87% (404). Analysis of the non-re-
sponders showed no differences between responders and non-responders with 
respect to the GP's recorded information on contact frequency and the presence 
of asthma-like symptoms, diagnoses and medication. Forty percent of the non-
responders were from ethnic minorities (Morocco and Turkey) compared with 
14% in the total population (p<.Ol). Presumably these parents had difficulties 
understanding the questionnaire. 
Of the 404 children for whom 
questionnaires were filled out, 
281 (70%) did not suffer from 
asthma. According to our crite-
ria, 98 (24%) were classified as 
having mild asthma, 17 (4%) as 
moderate and 8(2%) as severe 
asthma. 
Asthma symptoms were regis-
tered in 35% of the 464 GP files 
of children 1-4 years of age 
(table 2). The distribution of 
these asthma symptoms in the 
GP files is presented. There is 
some overlap between different 
items. Chest congestion with or 
without sputum production was 
registered most frequently, fol-
lowed by wheezing and 
rhonchi. In nearly 32% of all 
records the general practitioners 
prescribed specific asthma 
medication, including deptropi-
ne, an anticholinergic drug 
which is frequently prescribed in 
the Netherlands, but uncom-
mon elsewhere? The prescrip-
tion frequencies of specific 
asthma drugs are in table 3. For 
reasons of comparison with oth-
er countries, we present figures 
with and without deptropine. 
When deptropine prescriptions 
Table 2 
Number (%) of GPs' files (N=464) 
containing asthma symptoms 
All asthma symptoms 163 
· chest congestion/phlegm 74 
wheeze 63 
rhonchi 63 
nocturnal cough 37 
dyspnoea 35 
Table 3 
(35.1 ) 
(15.9) 
(13.6) 
(13.6) 
(8.0) 
(7.5) 
Number (%) of GPs' files (N=464) with 
specific asthma medication 
All asthma medication 148 
· deptropine 137 
All asthma medication 51 (deptropine excluded) 
beta-2-sympaticomimetics 34 
ketotifen 30 
· ipratropium bromide 7 
· corticosteroids 7 
· sodium-cromoglycate 5 
· xanthines 3 
Table 4 
Number (%) of GPs' files (N=464) 
containing asthma related diagnoses 
All asthma related 
diagnoses 
acute bronchitis 
chronic non-specific 
respiratory disease 
asthma 
93 
71 
43 
2 
(31.9) 
(29.5) 
(11.0) 
(73) 
(6.5) 
(1.5) 
(1.5) 
(1.1) 
(0.6) 
(200) 
(15.3) 
(93) 
(04) 
17 
Chapter two 
88l symptoms I!i!fj diagnoses I!i!fj medication I!i!fj combined 
% known 
100~-------------=",,-
80 
60 
40 
20 
o 
Figure 1 
mild (n=98) moderate (n=17) 
asthma severity 
severe (n=8) 
Proportion of asthmatic children known to GP, as indicated by registered symptoms, 
diagnoses and medication, per degree of asthma severity. 
were excluded the prescription of specific asthma medication consequently 
dropped from 32 to 11 %. Asthma related diagnoses were registered by GPs in 
20% of the files (table 4). Acute bronchitis was recorded most frequently. 
In order to answer the main question we compared questionnaire data with the 
GPs'records. Figure 1 gives the data from the records for each degree of asthma 
severity, as found in the parental questionnaire. All children with severe asthma 
were known to their GP. The proportion drops with falling levels of severity. 
Asthma-like diagnoses turn out to be registered in fewer children than both 
asthma symptoms and medication. For all classes of severity combined, 75% of 
children with asthma are known to their GPs. 
DiscLission 
The return of 87% completed questionnaires was similar to that of other studies 
on this sUbject.lO,l1 
By focusing on information recorded by GPs, we have restricted ourselves. When 
asking the GP directly, 'Does this child have asthma?' more cases would probably 
18 
Preschool children with asthma: are they known to their CPs? 
have been classified as 'known'. On the other hand, we suspect the latter 
method of data-collection to be more liable to bias than checking for information 
that was actually written down during patient care.15 
In this study, discrepancies between the two sources of information may be ex-
plained by the effect of time. As the diagnosis of asthma is seldom made in a sin-
gle consultation, there may be patients who are still on their way to being diag-
nosed by their GP among the children we have labelled as asthmatic. Another 
aspect of time worth mentioning, is reflected in the expectation that many chil-
dren with airway symptoms will grow out of them, especially in this age group, 
where viral infections may cause asthma-like symptoms. 16 
Of all items registered by GPs, medication is the best recorded. Recorded asthma 
medication was mostly deptropine, an oral drug with anticholinergic properties. 
Use of this drug accords with guidelines for asthma in childhood issued by the 
Dutch College of General Practitioners. 17 If deptropine had been unavailable (as 
in other countries), we assume that other drugs would have been prescribed. 
Antibiotics were excluded from our search, as their prescription for asthma is not 
advised. 
The limited number of practices included in our study means that the conclusions 
should be generalised with caution. As for the affiliation with the department of 
General Practice, the chance of selection bias will be small: several hundreds of 
practices have relations with the department for teaching, vocational training and 
research activities. None of the practices that participated in this study had been 
involved in any study in the field of childhood asthma before. 
Our results indicate that most children with probable asthma are known to their 
general practitioners, and that both registered asthma symptoms and specific 
asthma medication are a more sensitive pointer for detecting children with 
asthma from GPs' files than specific diagnoses of asthma or asthma-like disorders. 
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placebo-controlled trial of 
inhaled sodium cromoglycate in 
1-4 year old children with 
moderate asthma 
This study was funded by the Netherlands Asthma Foundation (grant no. 93.37). 
Drugs were provided by Fisons and Boehringer Ingelheim. Spacer devices were 
provided by Boehringer Ingelheim. 
Inhafed sodium crornogfycate in 7-4 year ofd chifdren with moderate asthma 
Introduction 
Respiratory diseases are an important cause of morbidity in preschool children.' 
The prevalence of asthma and persistent wheeze in children 1-4 years is between 
10 % and 20%,2,3 the variation apparently the result of differing definitions. Na-
tional and international consensus reports recommend sodium cromoglycate as 
prophylactic agent of first choice in young children with moderate asthma.'·5 
Sodium cromoglycate is a safe prophylactic drug that is widely used to treat 
asthma in children, although its mechanism of action is not fully understood.6.7 
Despite widespread use, the effect of inhaled sodium cromoglycate in very 
young children with moderate asthma has hardly been studied. Several placebo-
controlled trials have been reported but most were hospital-based, studied pa-
tients with severe asthma, had follow-up periods shorter than ten weeks, and 
studied medication inhaled by nebulisation. Six of these studies showed im-
provement of symptoms in comparison with placebo,B-13 but in five sodium cro-
moglycate was no better than placebo. 14-1B 
Data on the prescription of anti-asthma drugs in primary and secondary care 
show a trend of decreasing use of sodium cromoglycate and increasing use of 
inhaled steroids. 19 Because there is no convincing evidence that inhaled steroids, 
even in daily doses of less than 400 ~g, are without side-effects in the long-term 
treatment of young children, there is still a potential role for sodium cromogly-
cate for treating moderate asthma.20·21 Indeed, Konig and Schaffer22 suggested in 
1996 (based on a retrospective study) that treatment with sodium cromoglycate 
improves the long-term prognosis of childhood asthma. 
Nebulisation in young children is tedious and time consuming and therefore used 
mainly in severe asthma. The availability of spacer devices with face masks has 
extended the use of metered dose inhalers to children of preschool age. In the 
Netherlands most children with moderate asthma are treated by general practi-
tioners (GPs). Little is known, however, about the feasibility of and compliance 
with long-term prophylactic therapy when medication is inhaled through a spacer 
device and facemask at home in young children with moderate asthma. 
We undertook a study to investigate these issues in a comparison of inhaled so-
dium cromoglycate and placebo. 
Methods 
Children aged 1-4 years who had previously been on medication specifically pre-
scribed for respiratory problems (oral or inhaled bronchodilators, oral or inhaled 
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steroids, sodium cromoglycate or nedocromil sodium [though the latter is rarely 
used in young children], ketotifen, deptropine) were selected from the computer 
files of 151 GPs in the Rotterdam area. On behalf of the GP, we sent a postal 
questionnaire to each child's parents, enquiring about the child's symptoms and 
current anti-asthma medication. We defined moderate asthma as one or more of: 
more than 12 episodes of coughing, wheeze, or dyspnoea during the past year; 
use of anti-asthma medication; and at least two of the following three during the 
past month: coughing, wheezing or dyspnoea more than once a week; interfer-
ence of respiratory symptoms with daily activities; and interference of symptoms 
with sleep. Children who had been prescribed oral or inhaled steroids or who 
had been admitted to hospital for acute asthma in the past were classified as hav-
ing severe asthma. With the GP's approval, the parents of each child classified as 
having moderate asthma were asked to join the study. Exclusion criteria were 
congenital disorders and language difficulties (inability to speak Dutch ade-
quately). 
Children were enrolled from March 1995, to March 1996, to make sure the trial 
period included all four seasons. During the first visit, the research physician re-
corded the child's medical history and condition at that time, examined the respi-
ratory tract, ears, nose and throat, and measured height and weight. The parents 
gave written informed consent. 
Enrolled children entered a baseline period of four weeks, during which only res-
cue medication (ipratropium plus fenoterol aerosol; Berodual, Boehringer Ingel-
heim, Germany) was available. If the child was already using prophylactic medi-
cation, the baseline period was preceded by a washout period of 3 weeks. At the 
end of the baseline period the children were randomly assigned inhalation ther-
apy with either sodium cromoglycate or placebo, 10 mg (two puffs) three times 
daily with a spacer device and facemask (Aerochamber, Boehringer Ingelheim). 
Study medication (sodium cromoglycate and placebo) was prepared by Fisons 
pic, Loughborough, UK. We randomised in blocks of six patients and stratified for 
age, assigning blocks by years of age (1, 2 and 3 years). Parents were provided 
with rescue medication to be used in case of exacerbation. The study medication 
was given for five months. 
For use of the inhaler, parents were instructed to shake the canister and spray it 
into the spacer twice, with an interval of 5 s, fitting the facemask tightly around 
the child's nose and mouth as from the first actuation, and have the child breathe 
normally for 30 s. We instructed the parents to rinse the spacer device with tap 
water and allow it to drain, no more than once a week. 
During the trial, each child was visited at home once a month by a research 
nurse. During the visit the nurse checked the inhalation technique with the par-
ents, and asked about respiratory or other symptoms, side effects, difficulties with 
the spacer device, and visits to the GP or other clinician. Throughout the study, 
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treatment allocation was concealed from parents, patients, GPs, the research 
physician, and nurses. Since there is no suitable method of measuring the lung 
function in this age group at home, symptoms are the most relevant measure of 
the effect of treatment. 23 We asked parents to fill in a daily symptom-score list 
(panel) to record their child's asthma symptoms, limitation of activity during the 
day and at night, and use of trial and rescue medication. 
The primary outcome measure was proportion of symptom-free days in month 2 
- 5 of the intervention period. Other outcome measures were number of symp-
toms (possible scores 0-4 per day), use of rescue medication, loss of participants 
during the trial, need for additional medication, need for G P visits, referrals to 
secondary care and parent's guess about the type of treatment. We asked par-
ents of children withdrawn during the trial to continue filling in the daily symp-
tom-score list for the remainder of the trial period. 
All G Ps were advised to prescribe a short course of oral prednisone if asthma 
symptoms could not be controlled by trial or rescue medication. Reasons for 
withdrawing from the lrial were: more than one exacerbation that had to be 
treated with oral prednisone; prescription of long-term therapy with inhaled ster-
oids; and hospital admission for exacerbation, adenoidectomy or tonsillectomy. 
At the beginning of the trial we weighed a random sample of full canisters of 
study medication. After the trial all canisters were weighed on the same balance 
(Mettler AE260 deltarange® Tiel, the Netherlands) to assess compliance. 
A pilot study showed that children with moderate asthma had on average 
symptom-free day in 2, as in a study by Cogswell and colleagues.' To detect a 
difference in proportion of symptom-free days between cromoglycate and pla-
cebo of 20% at a significance level of 0.05 and a power of 80%, assuming an SO 
of 32%, as calculated from baseline symptoms scores, 40 children per group 
would be needed. We decided to enrol more children to enable the analysis of 
subgroups. 
Questions for daily symptom-score list 
Did you notice your child coughing or wheezing last night? yes/no 
Was your child awake because of coughing or wheezing last yes/no 
night? 
Did you notice coughing, wheezing or shortness of breath yes/no 
today? 
Did these airway symptoms interfere with the activities of yes/no 
your child? 
How often did your child inhale trial medication today? 0/1/2/3 times 
How often did your child inhale Berodual today? 0/1/2/3 or more times 
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The strategy for data analysis was written before the randomisation code was 
broken. Analysis was done by both intention·to·treat and on treatment. We ana· 
lysed the main efficacy parameter, i.e. proportion of symptom·free days, by a 
repeated measures analysis of covariance. This model involved both the mean 
response over the treatment period (to detect a possible treatment effect) and a 
linear trend (to detect a possible treatment by time interaction) of dependent 
variables. Independent variables were test medication (cromoglycate, placebo); 
gender; seasonal influence (autumn+winter/spring+summer); and smoking by 
parents; food allergy; eczema; experience with inhalation therapy; and positive 
family history (all nofyes). Age (months) and baseline value of percentage 
symptom~free days were used as covariates. Because of a possible violation of 
the normality assumption, we did the same analysis on arcsinsquare-root-
transformed outcome data.'" Separate analyses of subgroups were done for 
gender, age, and season. Differences in side effects and secondary effect 
measures were tested by X 2 test, t tests or Fisher exact tests (two·sided). 
The Medical Ethics Committee of Erasmus University Rotterdam/Academic Hos· 
pital Rotterdam approved the trial. 
Results 
2855 children who had previously been on specific respiratory medication were 
selected from 151 general practices (figure 1). The overall response rate to the 
questionnaire was 65%. Respondents and non-respondents were similar in terms 
of age and medication prescribed. 553 children (30% of respondents) met our 
inclusion criteria for moderate asthma. 104 were not invited to take part be-
cause the GP did not approve the inclusion (mostly because of social circum· 
stances, 20), because we could not contact the parents (43) or because of con· 
genital disorders (three), language difficulties (11), corticosteroid therapy (21), or 
an adenoidectomy/tonsillectomy planned in the near future (six). 449 children 
were invited to take part. 
Between March 1995, and March 1996, 232 children (42% of those with mod· 
erate asthma) entered the baseline period or washout period. 217 children did 
not start the trial; the parents of 72 children refused to participate because they 
expected feasibility problems, 109 did not want changes in therapy, 27 did not 
want any research, and nine refused for unknown reasons. A further 14 children 
were withdrawn during the washout or baseline period because the inhalation 
procedure was not feasible (three), the child had an exacerbation of asthma 
(five), an ear, nose, and throat procedure was planned (two), or other reasons 
(four). 218 children remained, of whom 109 were assigned sodium cromoglycate 
and 109 placebo. 
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The groups were similar except for baseline symptom score (table 1). During the 
trial period 51 children (23%; 28 in cromoglycate group, 23 in placebo group) 
were withdrawn (figure 1). 23 (37%) of the one-year-olds left the trial prema-
turely, compared with 11 (16%) 2-year-olds, and 17 (19%) 3-year-olds. The main 
reason for withdrawal of 1-year-olds out was the difficulty parents and children 
experienced in using the spacer device. Of the children who stopped prema-
turely, the parents of 38 (23 sodium cromoglycate group, 15 placebo group) 
kept recording symptoms, although 14 of them registered the daily symptoms for 
only part of the remainder of the trial period. 13 children (five sodium cromogly-
cate group, eight placebo group) were lost to follow-up. 167 (77%) children 
completed the trial. 
Table 1 
Characteristics of treatment groups at start of trial 
Mean (SO) age in years 
Number aged at entry 
12-23 months 
24-35 months 
36-48 months 
Male/female 
Medical history 
Mean (50)% symptom-free days during baseline 
period 
Perceived influence of season 
Eczema 
Food allergy 
Asthma also induced by exercise 
Experience with inhalation therapy 
Family history of asthma 
Family characteristics 
Parental smoking 
Mean (SD) age of mother on day of birth 
Of non-Dutch origin 
In day care 
Mean (SO) position in birth order 
Education mother low* 
Education father low* 
Anthropometry 
Mean (SD) length (em) 
Mean (SD) weight (kg) 
* ::; 4 years after primary school 
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Cromoglycate Placebo 
(0=109) (n=109) 
2.6 (0.9) 2.5 (0.8) 
34(31%) 31 (28%) 
32 (29%) 36 (33%) 
43 (39%) 42 (39%) 
58/51 64/45 
56.5 (31.3) 47.6 (33.2) 
50 (55%) 57 (52%) 
61 (56%) 63 (58%) 
48 (44%) 47 (43%) 
36 (33%) 36 (33%) 
40 (37%) 36 (33%) 
72 (66%) 58 (53%) 
73 (67%) 58 (53%) 
28.7 (4.5) 28.7 (4.1) 
5 (5%) 9 (8%) 
43 (39%) 49 (45%) 
1.85 (0.89) 1.94 (0.83) 
66 (61%) 71 (65%) 
44 (40%) 41 (38%) 
93 (9) 93 (8) 
15.9 (3.1) 15.5 (2.7) 
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Parents of 40 (37%) children in the cromoglycate group and 33 (30%) children in 
the placebo group reported side-effects (table 2). No serious side-effects were 
reported for either group by parents or GPs. Eczema around the place where the 
mask was applied occurred in five children in the cromoglycate group and none 
in the placebo group (p=0.052). Nine children in the cromoglycate group and 
one in the placebo group had coughing after inhalation (p=0.02). The frequen-
cies of other side effects were similar in the two groups. 
We estimated compliance from the weights of the returned canisters (mean for 
cromoglycate group 310 [SE 4J g, placebo group 311 [4J g). Of the children who 
completed the trial, 66 (81 %) in the cromoglycate group and 65 in the placebo 
group used more than 80% of the recommended dose (p=0.35). 
Averaged over month 2 - 5, the proportion of syrnptom-free days in the crorno-
glycate group was 65.7% (SD=25.3), compared to 64.3% (SD=24.5) in the pla-
cebo group (95% CI for difference, placebo rninus cromoglycate, -8.46 to 5.70). 
In both groups of children, the proportion of symptom-free days irnproved sig-
nificantly during treatment (paired t-test, p<O.O 1; 95% CI, treatrnent rninus base-
line, cromoglycate [5.1-17.5]' placebo [11.9-23.3 J). There was no significant dif-
ference in this increase between the groups (figure 2). The 95% CI for the differ-
ence between placebo and sodium cromoglycate (percentage symptom free 
days) adjusted for baseline value was -4.6 to 7.7. Analysis of covariance revealed 
no significant treatment effect, significant treatment by time interaction, or influ-
ence of age, gender, eczema, familiarity with inhalation therapy, seasonal 
influence or parental smoking on the overall proportion of symptom-free days. 
Baseline values were predictive of outcome. Analysis of the transformed data 
gave sirnilar results. On-treatment analysis was done by repeating the tests only 
Table 2 
Side effects 
Cromoglycate Placebo 
(n=109) (n=109) 
No side effects 69 (63%) 73 (67%) 
Behaviour 
More active 6 (6%) 12(11%) 
More sleepy 8 (7%) 5 (5%) 
Skin 
Eczema around nose and mouth 5 (5%) 0 
Other 7(6%) 8 (7%) 
Cough after inhalation 9 (8%) 1 (1%) 
Gastrointestinal 5 (5%) 6 (6%) 
Other 5 (5%) 4(4%) 
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Figure 2 
Mean (SE) proportion of symptom-free days, number of symptoms per day, and use of 
rescue medication 
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with children who had used more than 80% of the prescribed medication (66 
cromoglycate group, 65 placebo group). We could not find any significant 
differences in outcome (95%) CI of difference between placebo and cromo-
glycate -8.21 to 6.41). 
The number of symptoms per day and use of rescue medication per month 
showed no significant differences between the treatment groups (figure 2). Our· 
ing the trial, parents of children in the cromoglycate group reported 368 epi· 
sodes of illness, often with respiratory symptoms (164 episodes in 83 children). 
Parents of children in the placebo group reported 362 episodes of illness, 181 
(50%) with respiratory symptoms (88 children). 35 children in the cromoglycate 
group were taken to their GP about asthma (61 visits), compared with 47 chil· 
dren (85 visits) in the placebo group (p=0.14). Additional medication was used 
in 29 and 35 children in the cromoglycate and placebo groups, respectively: an· 
tibiotics (13 vs. 21), oral steroids (eight in each group), inhaled steroids (three vs. 
five), deptropine (five vs. six), promethazine (three vs. seven), salbutamol (six vs. 
one) and ketotifen (three vs. one). 
Growth, both linear and in weight, was similar in the two treatment groups dur-
ing the trial. 
29% of the parents of children in the cromoglycate group guessed the treatment 
correctly, whereas 37% of them thought their child had received placebo. In the 
placebo group, 30% of the parents guessed the type of treatment correctly, and 
33% thought their child had received cromoglycate. The remaining parents did 
not know. 
DisclIssion 
This study of long·term prophylactic inhalation therapy with a spacer device and 
face mask in 1-4·year·old children with moderate asthma showed that the treat· 
ment is feasible at home for such children, 77% of children in our trial used an 
inhaler for five months, and 78% of users took at least 80% of the recommended 
dose. Of those who stopped prematurely, 45% had difficulty in using the inhaler, 
particularly the l·year·olds. There were no differences in feasibility and compli· 
ance between the treatment groups. By contrast, Gibson and colleagues25 re-
ported poor compliance in a 2·month observational study in young children 
attending a paediatric respiratory clinic. In a study to assess compliance among 
adults receiving regular pulmonary medication in a general practice setting, 
Dekker and colleagues" could classify only 30% of the patients as compliant. We 
think that our better results could be explained by a selection bias of motivated 
parents and the intensive monitoring by the research nurses. 
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Both groups improved significantly in the proportion of symptom-free days. This 
finding can be explained by the placebo effect and the personal supervision as-
sociated with a clinical trial, as found previously in many trials in children. 
The two groups did not differ in proportion symptom-free days. We could not 
identify 'subgroups of children whose response to cromoglycate was influenced 
by age, gender, positive family history, atopic history, season or smoking habits 
of the parents. Geller-Bernstein and Levin" found an effect of cromoglycate in 
children aged 12 months and older, whereas no effect was seen in children 
below this age. 
Notable side effects of inhalation of sodium cromoglycate were cough directly 
after inhalation and eczema around the mouth. The first is well known, the latter 
was found previously in one of 29 children 15 . 
The lack of benefit from treatment with sodium cromoglycate in this trial may 
have resulted from the spacer device we used, which was an Aerochamber. Sev-
eral studies have shown a higher retainment of medication in this than in other 
spacer devices,27-29 so perhaps the dose of sodium cromoglycate reaching the 
lungs was inadequate in our trial. On the other hand, other studies have shown 
satisfactory drug delivery by this device in children. 3D•31 
There are few published data on assessment and monitoring early childhood 
asthma, probably because wheezing disorders in young children are ill defined. 
The limiting factor is our ability to measure the disorder itself. Most clinical meas-
urement schemes are based on symptom assessment, even though symptoms 
are non-specific and poorly defined and scoring systems have often not been 
adequately evaluated. 32 However, since symptoms are directly related to the 
burden of disease, we question whether other, more objective, measures of 
morbidity would be superior. 
We do not think the group size limits our conclusions. We can infer from the 
95% confidence interval that the difference between sodium cromoglycate and 
placebo, if any, is of no clinical importance. 
We conclude, therefore, that inhalation therapy three times daily with a spacer 
device in preschool children with moderate asthma is feasible, and that treatment 
with sodium cromoglycate via the Aerochamber is no more effective than 
placebo. We could not show any benefit of sodium cromoglycate treatment that 
balances the effort and cost of this therapy. Therefore we support the intentions 
of national and international guidelines committees to withdraw the recommen-
dation of sodium cromoglycate as the first choice in first-line inhaled prophylactic 
asthma treatment. 33 
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Practical aspects of a randomised controlled trial in general practice 
Introduction 
Randomised controlled trials are increasingly being performed in primary care 
and contribute to the body of evidence-based medicine.'·2 Trials in general prac-
tice enable collection of data from large populations of patients and, unlike hos-
pital-based studies, provide results that are relevant to clinical practice in a pri-
mary care setting.3 General practice has been promoted as an appropriate setting 
to evaluate interventions ranging from drug treatment to developments in health 
care services.',5 Morbidity in primary care differs from that in hospital care. Re-
ferrals to clinicians are rare for those diseases that occur frequently in general 
practice6 Of all problems presented to the GP, 90% will be treated within the 
general practice setting.' In 1997, 55% of all first prescriptions of drugs for 
asthma in the Netherlands originated from GPs.' 
For trials in general practice, two potential roles of the GP are defined: data col-
lector and project leader.' When a trial is sponsored by academic units or by 
industry, as is often the case in multicentre research, the GP generally takes care 
of recruitment and data collection. This offers the advantage that the logistics and 
financial planning and conformance with good clinical practice guidelines can be 
left to others. In Australia, Canada, and the Netherlands, GPs were interviewed 
about factors affecting their level of interest and activity in primary care research. 
The results showed that the workload is the most important factor"o.11 Although, 
research should involve a minimum of extra work for the GP, the biggest chal-
lenge of conducting a randomised controlled trial in general practice is the en-
rolment of patients6 ,12,13 The GP may be daunted by time-consuming and tedious 
extra work; instructing the patients, getting informed consent, executing the ran~ 
domisation, registering baseline and follow-up data, checking compliance, arrang-
ing appointments, etc. Actual recruitment usually lags behind the expectations 
once the trial has started; this phenomenon has been described as Lasagna's 
law.14 Trials may be suspended or prematurely ended due to unsuccessful re-
cruitment. An example of a trial that failed because of disappointing recruitment 
was reported by Tognoni et al.13 Another study that evaluated 100 (pharmaceuti-
cal) multicentre trials in general practice submitted to an ethical committee (1984 
- 1989) showed that recruitment of GPs and of patients was 61 % and 63%, re-
spectively, of the expected recruitment. 15 
In a primary care setting, we recently conducted a randomised controlled trial of 
inhaled sodium cromoglycate in 1-4 year old children with moderate asthma. We 
present the practical aspects involved in patient recruitment and follow-up, and 
the discrepancies between planning and actuality. By taking over the most time-
consuming activities, the workload of the GPs was minimised. We believe that 
our experiences can contribute to better planning in future research and more 
successful conduct of trials in general practice. 
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The study 
Brief outline and results 
We studied the feasibility and effects of long~term prophylactic inhalation therapy 
with sodium cromoglycate in preschool children. Children aged 1-4 years with 
moderate asthma were recruited through GPs in and around the area of Rotter~ 
dam between March 1995, and March 1996. After a 4~week baseline period, the 
children were randomly assigned cromoglycate or placebo, administered by in~ 
haler with spacer device and facemask for 5 months. Parents of the children 
completed a daily symptom score list. The primary outcome measure, the pro~ 
portion of symptom~free days for both groups, was greater for the treatment pe~ 
riod than for the baseline period. However, there was no difference between the 
sodium cromoglycate and placebo group, for the proportion of symptom~free 
days, or for any other outcome measure. A detailed report of this trial has been 
published elsewhere." 
Enrolment, inclusion and sample size 
Planned 
Children who had previously been on specific respiratory medication were se~ 
lected from the computerised records of GPs who held these records for at least 
one year. A pilot study (unpublished data) had shown that children with asthma 
are best found by conducting a search on specific respiratory medication, rather 
than a search on asthma diagnosis. On behalf of the GP, we sent a questionnaire 
to the parents of the selected children, enquiring about the child's symptoms and 
current medication. With the GPs' approval, the parents of each child classified 
as having moderate asthma on the basis of the questionnaire, were asked to join 
the study. In an average practice population of 2350 patients, 75 children aged 1 ~ 
4 years were expected.17 The pilot study showed that 5%, i.e. on average 4 chil~ 
dren in each practice, would meet the criteria for moderate asthma and two of 
these would be willing to participate. A study by Cogswell et al. 18 and our pilot 
study showed that children with moderate asthma have on average 50% symp~ 
tom-free days. Since the variance of this outcome measure was unknown, we 
based our calculation of the sample size on the assumption a dichotomous vari~ 
able, either symptom~free or not on the last trial day. To show an improvement of 
20% symptom~free days (i.e. 50 to 70%), with ex= 0.05 and ~ = 0.20, 91 children 
had to be analysed in each treatment group. We assumed a 40% dropout rate in 
view of the age of the children, and the intensity and duration of the treatment, 
and calculated that 150 GPs were needed to include 300 children. During 10 
months, 30 children had to enter the trial each month. 
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Actual 
Enrolment of GPs preceded the enrolment of children by 3 months. A total of 
160 GPs were asked to participate. They received an explanatory letter before 
being telephoned by the research physician (also a GP). Seven GPs were ex-
cluded because they were not computerised at that time. Only two GPs refused 
to participate, stating that they were not interested in asthma. Thus, 151 GPs, 
located in 109 practices, agreed to participate. Of these, 81 had a solo practice, 
36 worked together with one colleague and 34 GPs worked in 10 group prac-
tices. An average of 4 (range 1-10) telephone calls was needed to make the first 
appointment with a GP, in which mostly the computerised patient files were 
searched immediately. The mean number of children below four years of age 
was 160 (sd~l 00), i.e. 4.9% (range 2.0-9.0, sd~1.6) of the practice populations 
(data from 61 practices). The mean number of children with a prescription for 
anti-asthma medication selected in each of 109 practices was 26 (sd 20), i.e. 20% 
(range 3.0-50.0, sd~ll) of all children under the age of four (known for 61 prac-
tices). Questionnaires were sent to the parents of 2855 children asking about the 
child's symptoms and current medication. The percentage responders of the 
questionnaires sent to parents of the selected children was analysed by type of 
general practice (i.e. solo practice, duo, group) and urbanisation (city, town, vil-
lage) in a linear regression model, both univariate and multivariate. Because of a 
possible violation of the normal assumption, the percentage responders was 
transformed (arc-sin-square-root-transformation ).19 The overall percentage re-
spondents was 65.3% (range 12.9-100, sd~13.8). The response rate among pa-
tients of solo practices was 66.9% and of duo- and group practices 62.7% and 
56.5%, respectively. The difference was significant (p<0.05). Urbanisation was 
not a predictor of percentage responders. 
The mean number of children in each practice who met the criteria of moderate 
asthma was 5.1, (range 0-22, sd 4.2). Six GPs vetoed the participation of 20 chil-
dren, mainly due to adverse social circumstances; we were unable to contact the 
parents of 43 children, and 41 children met an exclusion criterion. A total of 449 
children were then invited to participate; a letter was sent to the horne before 
being telephoned by the research physician. Finally, 232 children (52%) started 
the baseline period and 218 (49%) were randomised; of these, 51 children (28%) 
stopped prematurely. On average 2 children from each practice were random-
ised (range 0-10, sd~2), 1.4 child per GP. Figure 1 shows the expected and ac-
tual patient inclusion and withdrawal. Because inclusion was slower than ex-
pected we extended the enrolment period from 9 to 12 months. We also recal-
culated the sample size because the premature dropout rate was lower than ex-
pected. The variance of the proportion of symptom-free days in the baseline pe-
riod of the first 90 children, enabled us to recalculate the sample size with a 
more appropriate formula. 20 Assumptions for improvement, a, and p remained 
the same. The recalculation revealed that only 40 children would be needed in 
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Figure 1 
Patient inclusion, planned and actual 
each group; we decided to continue recruitment to increase the power of sub-
group analyses. 
Randomisation 
Planned 
After the baseline period the children were randomised (based on order of entry) 
to either sodium cromoglycate or placebo, stratified for year of age. Medication 
was prepared by the pharmaceutical industry (in blocks of six) and blocks were 
assigned by year of age. Two copies of the full randomisation list were obtained, 
both in sealed envelopes; one was stored at the trial centre, the other was kept at 
the practice of one of the GPs. Furthermore, separate sealed envelopes for each 
randomisation number were stored in a similar way. 
Actual 
A total of 218 children were randomised. During the trial the code was broken 
twice, because hospital consultants considered it necessary to know the child's 
treatment in order to decide follow-up treatment after termination of the trial. 
The randomisation presented no other problems. 
Follow-up 
Planned 
During the first home visit, the research physician explained the trial to the par-
ents, asked informed consent, and recorded the child's history and condition. If 
40 
Practical aspects of a randomised controlled trial in general practice 
160 
146 141 
140 131 133 132 127 134 
124 
120 
104 
96 99 
'" 
100 
.~ 
S 79 
W 80 71 67 
E 
0 60 49 
-'" 46 
40 34 26 
20 
0 
2 3 4 5 6 7 8 9 1 0 11 12 13 14 15 16 17 18 19 
trial months 
Figure 2 
Home visits during the trial 
the child was already using prophylactic medication, the baseline period was 
preceded by a washout period of 3 weeks. During the trial period each child was 
visited at home once a month by a research nurse who checked inhalation tech-
nique, symptom score lists, asked about condition and side effects and provided 
the medication for the next month. The GP stayed in charge of primary care; he 
was advised by the research physician to prescribe a short course of oral predni-
sone if asthma symptoms could not be controlled by trial or rescue medication. 
Throughout the study, treatment allocation was concealed and GPs were in-
formed several times about their patient and the trial. 
Actual 
During the baseline period 14 children dropped out, they were visited only 
twice. The 218 randomised children were visited 8 times at home, first by the 
research physician and subsequently by the research nurse: once prior to the 
baseline period, once at the start of month 1 (randomisation) and subsequently 
at the end of each trial month until the end of the fifth month. During the trial, 51 
children dropped out prematurely. Of these, 38 parents continued to record 
symptoms and 13 parents did not. The research nurses made 14 additional visits 
because spacer devices were lost or defect, or side effects were reported that 
needed an immediate check. A total of 1737 home visits were made (figure 2). A 
home visit generally took 30 to 60 minutes. The mean distance for a home visit 
was 18 km, amounting to 68000 km during the trial. One research nurse was 
occupied for 20 months, a second nurse for 8 months. They both worked 80% 
and on average made four home visits per day, conducted appointments, mail-
ings, data entry, etc. 
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The GPs were updated at least four times about their patients; at inclusion, after 
randomisation, during the trial, and at the end of the trial period. In addition, 
three newsletters were sent to all GPs reporting of trial progress and preliminary 
results. Finally, all G Ps received a reprint of the published results. 
Comment 
Although adjustments were made in the recruitment phase, we conclude that this 
randomised controlled trial in general practice worked out well. Our planning 
underestimated the logistics of recruitment of GPs and subsequent patient re-
cruitment, and we did not allow for a moderate response rate to the question-
naires. It was necessary to extend the recruitment period by three months; in-
stead of 2 eligible children per participating GP, we actually recruited 1.4 child 
per GP. On the other hand, the sample size and the dropout rate were lower 
than expected. Currently, in the Netherlands 80% of GPs employ electronic 
medical records." Most of the invited GPs agreed to participate (99%), probably 
because of our assurance that their extra workload would be minimal. The per-
centage responders was lower for patients of GPs working with colleagues than 
for solo practice GPs. This finding could not be confirmed by other reports, but 
an explanation could be that patients feel more obliged towards a solo practice 
GP. 
We conclude that this trial was successful mainly because of a relatively passive 
role for the GP. This was reached in three ways. Firstly, we were almost inde-
pendent of the GP in recruiting children; the research physician searched the 
GPs electronic medical records for data on prevalent illness. From then on all 
activities necessary for recruitment were steered by the researchers. An example 
of another trial with cases selected from data on prevalent illness is that reported 
by Walma and colleagues;22 they included 202 patients receiving long-term diu-
retic therapy, identified by scanning the pharmacy registers of general practices. 
Especially in general practice, trials with patients that can be selected by diagno-
sis or medication already prescribed may be more successful in recruiting pa-
tients than trials that evaluate interventions of incident diseases. Peto and col-
leagues23 asked GPs to recruit patients requiring treatment for menorrhagia and a 
review of six general practices revealed that only 20% of the 196 eligible patients 
had been recruited. Secondly, we were independent of the GP in collecting data 
from the participants during the follow-up period. All contacts were arranged 
directly between the research physician or nurse and the parents. Although we 
conducted instructions, medication distribution and randomisation, the GPs 
stayed in charge of primary care and were well informed about their patients 
throughout the trial. Thirdly, all patients were visited at home. In a trial investigat-
ing otitis media, young children had to report to a clinic for a diagnostic proce-
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dure; problems with transportation, lack of time and lack of care for other chil-
dren were reasons for parents not to participate.24 Volmer and colleagues25 re-
cruited families of children with asthma; only 55% of the children scheduled for 
randomisation visits in the clinic attended the initial appointment. There are other 
advantages in being independent of the GP at an early stage of the trial. For ex-
ternal validity of the study results it is important to record the selection of eligible 
patients in the phas,e prior to inclusion.6,26 We were able to give a uniform report 
on the difference between eligible and enrolled patients because we had con-
tacted all respondents. The degree of willingness of GPs to participate does not 
guarantee enrolment of eligible patients; Kuyvenhoven et al.'" reported that 24% 
of the GPs who participated in their study on sore throat enrolled no patients at 
all. In the clinical trial prepared by Tognoni and colleagues13, on the treatment of 
isolated systolic hypertension in the elderly, 806 GPs agreed to participate but 
only 63 started recruitment activities; the authors suggest that the change in atti-
tude of GPs from the role of reassuring prescriber to one of uncertainty led to 
withdrawal of GPs. This factor may also be reduced when the researchers take 
over all pragmatic aspects of the trial. Randomisation must be centralised; in 
most multicentre trials this is best done by telephone or by a computer link." In 
our case, the researchers were directly responsible for the randomisation without 
interposition of the GP. 
We conclude, therefore, that our approach of conducting a randomised con-
trolled trial in general practice was successful because we recruited from com-
puterised data on prevalent illness, and undertook the tasks of recruitment, inclu-
sion and follow-up without bothering the GP. 
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Feasibility of fang-term inhalation therapy in preschool children with moderate asthma 
Introduction 
Current guidelines recommend inhalation therapy as the preferable way to ad-
minister medication to children with asthma.' The availability of spacer devices 
with face masks has extended the use of metered-dose inhalers (MDls) to chil-
dren of preschool age. The preference for an MDI with spacer and face mask 
above a nebuliser is reflected in guideline recommendations for preschool chil-
dren. 1 Studies have shown that spacer devices are as effective as nebulizers.2,) 
Various spacer devices with face masks are available and the delivered dose var-
ies considerably between devices and intended age groups. The choice of spacer 
depends mainly on convenience, compliance and parental preference.' Especially 
in young children adherence to therapy largely depends on parental commit-
ment. 
Achieving control in children with asthma is difficult, as reflected in increasing 
morbidity and hospitalisation rates, and the increasing use of effective anti-in-
flammatory therapies. 4.7 There are many reasons for a poor response to treat-
ment, but one increasingly recognised problem is failure to adhere to the pre-
scribed treatment. Compliance and patient/parent-adherence have been under-
exposed, partly because methods of measuring compliance are often inade-
quate.B•9 Data on the feasibility of inhalation therapy in young children are even 
scarcer; in this case the selection of children and their tolerance of the spacer 
device are important issues. Nonadherence has considerable consequences for 
morbidity, clinical trial outcomes and costs of treatment. 
Compliance with inhaled asthma treatment is generally poor. The extent to which 
asthma patients follow prescribed treatment plans is reported to range from 30 
to 70%.8 After reviewing the prescriptions of nearly 18,000 children (aged 4-17 
years) with asthma, Warner showed that 52% had been prescribed preventive 
treatment but only 15% received sufficient repeat prescriptions to suggest that 
they regularly adhered to the treatment.s Another study reported a compliance 
rate of almost 60% in children receiving prophylactic medication during 13 
weeks.1O Gibson et al. hypothesised that parental involvement in drug administra-
tion to preschool children would result in better compliance, but reported poor 
results with inhaled prophylactic therapy during two months in 26 children at-
tending a hospital; they suggested that their results might even have overesti-
mated true compliance. ll 
little is known about the feasibility of and compliance with long-term prophylac-
tic inhalation therapy through a spacer device and facemask in young children. 
Therefore, we investigated the feasibility of and compliance with 5 months of 
inhalation therapy, 3 times daily, in 1-4 year old children with moderate asthma. 
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Methods 
The study question was addressed within the context of a randomised trial of 
sodium cromoglycate that has been reported elsewhere. 12 The Medical Ethics 
Committee of Erasmus University/University Hospital Rotterdam approved the 
trial. Children with moderate asthma were selected from computerised medical 
files of general practitioners (GPs) in the Rotterdam area, containing data on pre-
scribed asthma medication and recorded asthma symptoms. Children who had 
been prescribed oral or inhaled steroids were classified as having severe asthma 
and were not approached. The parents of children classified as having moderate 
asthma were asked to participate in the study; they received a letter before they 
were telephoned and visited by the research physician. The participating parents 
gave written informed consent. Children who were enrolled entered a baseline 
period of four weeks after which they were randomly assigned to inhalation ther-
apy with either sodium cromoglycate or placebo, three times daily 10 mg (two 
puffs), using a spacer device and face mask (Aerochamber®). Parents were pro-
vided with rescue medication (ipratropium+fenoterol aerosol (Berodual®)) to be 
used in case of exacerbation. The trial was designed to cover a 5-month period. 
To use the inhaler, parents were instructed to shake the canister and spray it into 
the spacer twice, with an interval of five seconds, fitting the face mask tightly 
around the child's nose and mouth from the first actuation, and have them 
breathe normally for 30 seconds. Parents had to fill out a daily symptom score list 
recording the child's asthma symptoms and limitation of activity during the day 
and night, and use of trial and rescue medication. During the trial the children 
were visited once every month at home, the first time by the research physician 
and subsequent visits by a research nurse. During each visit the nurse checked 
the inhalation technique with the parentis), asked about respiratory or other 
symptoms, side effects, concurrent medication, problems with the spacer device, 
and visits to the GP or clinician. The child's medication for the subsequent month 
was delivered at each visit. Eight months after the trial period, parents of all chil-
dren were interviewed by telephone about symptoms and medication. During 
the trial, GPs were advised to prescribe a short course of oral prednisone if 
asthma symptoms could not be controlled by trial or rescue medication. Reasons 
for withdrawing from the trial were: more than one exacerbation treated with 
oral prednisone; prescription of inhaled steroids; hospital admission due to exac-
erbation, adenoidectomy or tonsillectomy. Parents of children who dropped out 
or were withdrawn during the trial were asked to complete the daily symptom 
score list for the remainder of the trial period. 
Fifty full canisters, a random sample of the study medication, were weighed; 
variation in weight was negligible (sodium cromoglycate: mean= 25.86 g sd= 
0.070 g, placebo: mean= 25.73 g sd= 0.097 g). After the trial all canisters were 
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weighed using the same balance (Mettler AE260, Deltarange®, Tiel, the Nether-
lands). 
Outcome measures used to assess feasibility were willingness to participate in 
the trial, loss of participants during the trial, and percentage of medication taken 
(both reported by the parents and calculated for weighing canisters). 
Compliance was calculated for all children who completed the trial. We defined 
weight compliers as subjects who used at least 80% of the prescribed dose based 
on the weight loss of the canisters, and note compliers as children who used at 
least 80% of the prescribed number of puffs as reported by the parents on the 
daily score lists. To compare our results with other studies we calculated day 
compliance (the proportion of days of strict adherence to the prescribed regi-
men) and dose compliance (administered doses as a proportion of total pre-
scribed doses over the entire study period). 
The influence of patient characteristics on premature withdrawal and on compli-
ance, according to the definitions above, was evaluated by means of a logistic 
regression analysis with age, gender, medication (placebo/cromoglycate), side-
effects, eczema, food allergy, birth order, age and education level of mother, age 
and education level of father, smoking habits of the parents, day care, family his-
tory and baseline severity as explanatory variables. To evaluate how much varia-
tion in the number of puffs reported by the parents could be explained by weight 
loss of the canisters, a Poisson regression analysis was carried out. 13 For each pa-
tient, we computed the mean number of reported doses per day and the mean 
number of doses per day estimated from the weight loss of the canisters; the re-
lationship was tested with a Wilcoxon signed rank test. Mann-Whitney tests were 
used to analyze the relation between compliance and the experienced episodes 
of respiratory illness, as reported during the home visits. We evaluated whether 
the number of symptoms on the same and the previous day predicted the com-
pliance, by a logistic regression for repeated measurements (SAS Proc Genmod). 
Results 
The effectiveness of sodium cromoglycate in this trial has been reported in detail 
elsewhere; no differences were found between sodium cromoglycate and place-
bo treatment. 12 
From medical records of 151 general practitioners, 553 children met our criteria 
for moderate asthma. Of these, we invited 449 to participate in the trial and fi-
nally 232 children entered the baseline period. Reasons for not being invited and 
not participating are listed in Table 1. Participants and non-participants were 
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comparable with regard to age, gender and medication prescribed. Fourteen 
children dropped out during the baseline period; of the remaining 218 children, 
109 were randomised to receive sodium cromoglycate and 109 to receive 
placebo. 
Table 2 lists the patient characteristics. During the trial period, 51 children (28 in 
the cromoglycate group and 23 in the placebo group), dropped out or were 
withdrawn for similar reasons in both groups. In total 37% of the one-year-olds 
dropped out prematurely, compared with 16% and 19% of the two- and three-
year-aids, respectively. The main reason for withdrawal of the one-year-olds was 
difficulty in using the spacer device (Table 3). 
Characteristics of withdrawals due to feasibility problems were younger age 
(year) of the child (odds ratio~ 2.6, p~O.003), and lower education level (low ver-
sus high) of the mother (odds ratio~ 5.0, p~0.013). Gender, eczema, food allergy, 
Table 1 
Reasons for non-participation and non-completion ofthe trial (Values are numbers of 
children) 
Returned questionnaire and classified as moderate asthma 
Not invited 
No contact parents 
Disapproval GP 
Exclusion criteria: 
congenital disorders 
language problems 
on steroid therapy 
planned ENT procedure 
Invited to participate in the trial 
Parents not willing to participate 
Expected feasibility problems 
Wanted no changes in current treatment policy 
Recent ENT procedure 
Wanted no research, feared side effects 
Unknown 
Started baseline period 
Dropped out 
Feasibility problems 
Medical reasons 
Other 
Randomised 
Dropped out 
Feasibility problems 
Medical reasons 
Completed the trial 
50 
104 
43 
20 
3 
11 
21 
6 
217 
72 
99 
10 
27 
9 
14 
3 
7 
4 
51 
30 
21 
553 
449 
232 
218 
167 
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birth order, age of mother, age or education level of father, smoking habits of the 
parents, family history, day care, baseline severity, side-effects or medication 
(cromoglycate or placebo) were not related to withdrawal. Finally, 167 children 
completed the study. 
Weight compliance 
Of the 167 children, 131 (78%) used over 80% of the recommended dose. Pres-
ence of eczema (odds ratio ~ 2.6, p~ 0.019) was a significant predictor of better 
compliance. No other patient characteristics had any influence on compliance. 
Note compliance 
Parents of 119 (71%) children registered that 80% of the total prescribed dose 
had been taken. None of the patient characteristics showed a significant odds 
ratio, although eczema yielded a borderline significant result (odds ratio ~ 2.1, 
p~0.055). The proportion of days of full adherence to the prescribed dose (day 
compliance) was 62%, and the proportion of the total dose actually administered 
over the entire study period (dose compliance) was 81%. Table 4 shows a cross-
tabulation of note compliance and weight compliance; agreement in classifica-
tion was found in 84% (Kappa ~ 0.59, SE~0.071, p<O.OOl). 
Table 2 
Patients' characteristics 
Cromoglycate 
Age in years; mean [sdJ 2.6 [0.9[ 
Male(%) 53 
Eczema (%) 56 
Experience with inhalation therapy (%) 37 
Education mother low (%) 61 
Education father low (%) 40 
Table 3 
Reasons for withdrawal according to age of the children 
Number of children in trial 
Number of children withdrawn 
Feasibility problems 
Medical problems 
1 year 
63 
23 (37%) 
17 (27%) 
6(10%) 
Placebo Total 
2.5 [0.8[ 2.6 [0.8[ 
59 56 
58 57 
33 35 
65 63 
38 39 
Age 
2 years 3 years 
69 86 
11 (16%) 17(19%) 
7 (10%) 6(7%) 
4 (6%) 11(12%) 
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Table 4 
Comparison of 80% compliance based on canister weight loss versus parent reports. 
(Values are numbers of children.) 
Note complier no 
yes 
Weight complier 
no yes 
29 19 
7 112 
36 131 
48 
119 
167 
Relation between note compliance and weight compliance 
The Poisson regression yielded an R' of 0,64, indicating that 64% of the total 
variation in the registered number of puffs could be explained by the estimated 
relation with final weight loss of the canisters, Figure 1 shows individual mean 
reported daily dose versus the daily dose calculated from weight loss, The mean 
daily dose of trial medication was 2.5 times 2 puffs per day (sd~0,5) as registered 
by the parents, Again, there were no significant differences between the two 
treatments, The mean daily dose based on weight was 2.7 times two puffs per 
day (sd~0,9) (Wilcoxon rank test p<0,0005), The number of symptoms predicted 
compliance with preventive medication on the same day (odds ratio: 1.1 per 
symptom, p~0,015), which means an every symptom increased the odds on 
compliance by 10%, A similar relation was shown when the number of symp-
toms on the previous day was taken as a predictor (odds ratio: 1,1, p~O,Oll), 
In 29% of the (5x167~835) home visits during the treatment period parents re-
ported respiratory episodes in the previous month, Parents of weight compliers 
reported more respiratory episodes (mean 1,6) than non-weight compliers (mean 
1,1) (Mann-Whitney test p~0,03), 
Eight months after the end of the trial we interviewed the parents of 208 children 
by telephone, Of them, 90 judged the asthma status of their child to be the same 
as or worse than in the previous year; 104 children still used inhaler medication 
administered with a spacer device (mostly an Aerochamber®); 44 children used 
inhaled preventive medication and 84 children used inhaled bronchodilators, 
Discussion 
This study on long-term prophylactic inhalation therapy with a spacer device and 
facemask in a large group of children (aged 1-4 years) with moderate asthma 
showed that such treatment is feasible in selected children, Nearly 80% of the 
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Figure 1 
Plot of individual mean reported daily dose versus the daily dose as calculated from 
weight loss 
children used more than 80% of the medication prescribed. Compared with 
similar data on this age group, this compliance rate is rather high. Gibson et al. 
found a variable and often poor compliance with inhaled prophylactic therapy in 
their hospital-based study in preschool children." They observed 26 children 
during 2 months and used diaries and electronic timers to assess compliance; 
they reported a day compliance of 50% and a dose compliance of 77%. In our 
study, day compliance and dose compliance were 62% and 81 %, respectively, 
during 5 months. Coutts et al. measured compliance in 14 asthmatic children, 
(aged 9-16 years), during 1 to 3 months by means of diary cards and electronic 
devices; they found under-use of inhaled prophylactic medication in 55% of the 
study days." Milgrom et al. found the median actual use of inhaled steroids to be 
58% in 24 children aged 8-12 years.'o 
The good compliance in our study may be attributed to three factors. Firstly, in 
the recruitment phase prior to randomisation, selection based on parental moti-
vation was made. Of all eligible children whose parents did not participate, 32% 
refused because they expected feasibility problems. Secondly, during the trial, 
59% of the children who prematurely ended the intervention period, withdrew 
because of feasibility problems. Thirdly, participation in the trial probably im-
proved compliance with treatment lS due to regular home visits, and detailed in-
formation about the therapy. 
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On the other hand, sodium cromoglycate treatment showed no beneficial effect 
compared to placebo and the prescribed regimen of trial medication was de-
manding: 3 times daily 2 puffs. It has been reported that regimens involving dos-
ing once or twice daily result in better compliance. 14,16,17 Gibson et al. 11 did not 
find this relationship, but in case of 3 prescriptions daily the middle dose was 
often omitted; the same result was shown by Milgrom et al. 1O for inhaled steroids 
in children. 
Measuring compliance is difficult; the most common measures used to assess 
patient adherence with asthma therapy are self-report by diaries, electronic 
measurement and medication measurement. An electronic timer device counts 
and times each actuation of an MOl and can be used with all types of aerosol 
canisters allowing direct monitoring of inhaler use. Both weighing and electronic 
measuring can be confounded by actuations into the air, e.g. test firing before 
actual inhalation of drug or canister dumping by successive firing.'" Braustein et 
al. used all three measurements and found that both canister weight and patient 
reports overestimated compliance compared with the electronic device. Apart 
from physician assessments, patient diaries may be less reliable than other meas-
urements because over-reporting by the patients and by parents is com-
mon. 1O,II,14,19-20 Strikingly, in our study the parents under-reported the use of 
medication compared with canister weights. This under-reporting was expressed 
by the difference between note and weight compliance (Table 4), by mean daily 
dosages based on parents' reports and weights (2.5 versus 2.7), and by the 
scatter diagram of individual points (Figure 1). The points on the right side of 
Fig.l probably represent test firing or canister dumping, rather than overdosing. 
None of the parents reported more than three daily doses, because the score list 
did not provide for this option. 
Our study shows a weak, but significant relation between compliance of inhaled 
prophylactic medication and number of symptoms on the same day and the 
previous day: every symptom increased the odds on compliance with 10%. We 
realise that due to the large study population and the large number of trial days 
our test was powerful. It is likely that symptoms alert the parents to give medica-
tion. Also, the reported respiratory episodes were a predictor of better com-
pliance. Apparently, parents of young children with moderate asthma who are 
reminded by their child's symptoms will become more compliant in adminis-
tering prophylactic medication to their child. Other studies show no relation with 
symptoms.",21 In the study by Milgrom et al.1O compliance with inhaled steroids 
showed that low compliance was associated with exacerbation of asthma. 
The unpopularity of preventive medication, rather than unpopularity of method 
of administration, was demonstrated by our follow-up data. Although 43% of the 
parents indicated that their child had the same or worse symptoms during the 
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eight months after the trial period, nearly all used a spacer device with facemask 
for their bronchodilators, but only 21 % still used preventive inhaler medication. 
Moreover, 76% of the parents indicated they preferred to use bronchodilators 
more often rather than use preventive medication for their child every day. 
To our knowledge, this study is the first to establish the presence of eczema as a 
predictor of better compliance; parents may be extra motivated by seeing the 
child with symptoms of a related disease. No other patient characteristics, or 
baseline severity and medication (placebo or cromoglycate) were predictive of 
note compliance or weight compliance. In the study by Gibson et al." day care 
had a significant adverse effect on dose compliance but not on day compliance, 
indicating a poorer overall parental compliance in children who attend day care. 
In our study, whether children were cared for at home or nursery had no signifi-
cant effect on drug administration. 
We conclude that long-term inhalation therapy with spacer device and facemask 
is feasible in selected 1-4 year olds and that compliance can be relatively high in 
a selected and well-supported group. Lower age of the child and lower education 
level of the mother are risk factors for treatment failure. Children who experience 
more respiratory symptoms or have eczema show better adherence to the pre-
scribed regimen. 
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Introduction 
Many young children have one or more episodes of wheezy breathing before 
the age of four, often associated with viral respiratory illnesses.' Two thirds of 
these children, especially those with milder symptoms, will not have asthma after 
the age of six.' Apart from symptoms, there are no suitable tests that can rou-
tinely be applied at preschool age. Therefore, it is important to assess the rela-
tionship between the pattern of morbidity and disease evolution, including com-
pliance with treatments. The aim of our study was to investigate whether predic-
tors of long-term adherence to inhaled asthma prophylaxis can be found in 
young children with moderate asthma in general practice. 
Patients and methods 
Children aged 1-4 years, recruited through 151 general practitioners (GPs) be-
tween March 1995 and March 1996, participated in a randomised placebo con-
trolled clinical trial that evaluated the effects of sodium cromoglycate inhalation 
therapy by means of a spacer device and face mask, during 5 months. 3 The diag-
nosis moderate asthma was based on prescriptions of anti~asthma medication in 
the past, and on symptoms and medication at entry. At the beginning of the trial, 
the child's medical history was recorded and during the trial parents daily re-
corded their child's respiratory symptoms and use of rescue medication (bron-
chodilator). During monthly home visits by a research nurse, the parents were 
asked about visits to the GP. The detailed methodology and results of this trial 
have been reported elsewhere. 3 After the trial, continuing prophylactic treatment 
was decided by the patient's own GP and not influenced by the research team. 
Fourteen months after the baseline assessment (8 months after the trial) the par-
ents were contacted by telephone and follow-up data were obtained about 
asthma medication during the previous six months. We compared children who 
still used inhaled prophylaxis (cromoglycate or steroids) 14 months after start of 
the trial with those who had been without prophylaxis with respect to patient 
characteristics (age, gender), data recorded at the start of the trial (height and 
weight, provocation of symptoms by exercise, siblings with asthma, history of 
parents for asthma and atopy, reported eczema and food allergy, attendance at 
day-care, parental cigarette smoking) and morbidity characteristics during the trial 
(sum of symptoms per day, percentage of symptom-free days, use of inhaled 
bronchodilator per day, number of episodes, duration of episodes, number of GP 
consultations for respiratory and non-respiratory reasons). An asthmatic episode 
was defined as a period of at least 4 consecutive days with at least 3 out of 4 
symptoms each day. Finally, the number of children receiving cromoglycate dur-
ing the trial was compared for both groups. The differences were tested by 
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means of logistic regression analysis. We calculated odds ratios with 95% confi-
dence intervals (Cis). 
Results 
Of the 218 children who had participated in the clinical trial 208 were reached 
by telephone eight months after the trial had finished. We were unable to trace 
10 children whose age, gender and other outcome measures for asthma symp-
toms during the trial were similar to the children contacted. Of these 208, 44 
children were still using prophylactic inhalation therapy. Data of this latter group 
were compared with those of 164 children who were without prophylaxis. Figure 
1 shows the differences between the groups with odds ratios and 95% Cis. 
Characteristics not mentioned in Figure 1 were similar for both groups. 
Discussion 
In this study, 21 % of the children had continued prophylactic inhalation treat-
ment 14 months after the start of the trial. To our knowledge this study is the first 
to investigate to what extent morbidity characteristics of preschool children with 
moderate asthma predict long-term adherence to inhaled prophylactic treatment. 
The differences found in morbidity characteristics suggest that these children ini-
tially had more troublesome symptoms: longer and more frequent respiratory 
episodes, more frequent use of bronchodilators and more frequent consultations 
for respiratory complaints, whereas the overall main outcome measures of the 
trial (proportion symptom-free days and sum of daily symptoms) were similar in 
both groups. A surprising finding was that children on inhaled prophylaxis at fol-
low-up were less likely to have attended day-care. We speculate that the more 
troublesome the disease is, the less likely that the parents will arrange day-care 
for their child. Another explanation might be that children who attended day-care 
had more infections and therefore less asthma at follow-up.' 
Several large cohort studies have shown that the more severe the asthma, the 
less likely it will be outgrown.'·s" Exercise as a provoking factor for asthma symp-
tomss and asthmatic parent(s) have been recognised as risk factors for persisting 
asthma. 2,6 
We conclude that several characteristics from history and morbidity in preschool 
children with moderate asthma in a general practice setting predict adherence to 
prophylactic inhalation therapy after 14 months, and that these correspond with 
known risk factors for persisting asthma symptoms. 
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Determinants of long-term used of inhaled prophylaxis in preschool children with 
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Introduction 
Several guidelines for the management of childhood asthma have been published 
by international consensus groups, recommending early preventive treatment to 
reduce the need for bronchodilators and to enable asthmatic children to lead a 
normal and active Iife. I ,2 The consensus statements recommend sodium cromo-
glycate (SCG) as maintenance treatment of children with moderate asthma. SCG 
is supposed to be effective in 60% of the cases/ but predictors of success are 
not known. Although SCG has been used for decades, the precise mechanism of 
action is still not fully understood. No serious side-effects have been reported in 
trials, but dysuria, urticaria, bronchospasm, angio-oedema and anaphylaxis can 
occUr.4,S,6 
In a recently published review and position statement of the British Asthma Co-
ordinating Committee, SCG and corticosteroids were both posited as first choice 
preventive therapy in young children, rather than recommending use of SCG as 
first choice before inhaled corticosteroids;' the grounds for this decision are, 
however, still unclear. The long-term side effects of preventive asthma treatment 
with inhaled steroids in early childhood are unknown. Nevertheless, there is con-
cern that treating very mild cases of asthma with inhaled steroids may have an 
adverse effect on the balance between risk and benefit; therefore sodium cro-
moglycate may still be considered as first choice preventive treatment.' Other 
recent guidelines continue to recommend SCG as first choice in young children.' 
The use of SCG has decreased since 1990, while the use of inhaled corticoster-
oids is increasing (even in young chiidren)9.10 Nowadays, few consultant paedia-
tricians use cromoglycate as first-line treatment in young children, I I whereas 
some studies suggest overtreatment of children with mild asthma with inhaled 
corticosteroids.9oll 
The discrepancy between guidelines and daily practice, and the debate on the 
role of SCG, which led to its recent withdrawal as first line treatment in young 
children, Was the rationale to review the effectiveness of SCG in the treatment of 
childhood asthma. We systematically reviewed all published randomised place-
bo-controlled trials of SCG in the prophylactic treatment of asthma in children. 
The aim of the study was to assess the methodological quality of the studies and 
the effectiveness of inhaled sodium cromoglycate by statistical pooling of the 
study results. 
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Methods 
Selection of studies 
Literature searches of Medline, Embase, the Cochrane Controlled Trial Register]] 
and the database of the pharmaceutical company manufacturing SCG were car-
ried out for the period January 1966 to December 1997. The MESH-keywords 
[asthma], [sodium cromoglycate] and [clinical trial] were used to identify relevant 
articles. After the search we reviewed the reference lists of all relevant articles 
and all double-blind placebo-controlled, randomised clinical trials were selected 
which included children aged 0-18 years old, which addressed maintenance 
therapy, and were published in English. 
Methodological assessment 
All trials were scored according to the criteria listed in Table 1 and Appendix 1. 
The scoring method was based on the well-known principles for assessing the 
quality of intervention research. 14 For a number of criteria a weighting system 
was used, giving a maximum score of 95 points for a study.15 Table 1 shows the 
eight categories into which the items were arranged. We decided that the items 
'proper retrospective analysis' and 'multiple looks considered' from the original 
scoring list were not applicable because these procedures are uncommon in 
studies addressing prophylactic asthma therapy. In crossover studies we consid-
ered the presentation of prerandomisation characteristics to be less important 
than in parallel studies, thus the maximum score in crossover studies was 94 in-
stead of 95. 
Table 1 
Criteria for the methodological assess-
ment of randomised controlled trials 
(For details, see Appendix 1.) 
Criterion Weight 
A Selection and inclusion 6 
B Randomisation procedure 13 
C Blinding 23 
D Intervention 6 
E Withdrawals 7 
F Compliance 6 
G Statistics and analysis 24 
H Presentation of results 10 
Total 95 
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The methodological quality of the 
studies was assessed independently 
by two (MJAT, JHJMU) of the three 
reviewers, two general practitio-
ners and a methodologist. Before 
scoring the trials the reviewers 
mutually adjusted their interpreta-
tion of the items. The results were 
discussed in a consensus meeting; 
in case of lack of consensus the 
assessment of the third reviewer 
(JCvdW) determined the final de-
cision. To avoid "reviewers1 review 
bias" our own trial 16 was also 
scored by an impartial reviewer 
(SMA Bierma-Zeinstra). 
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Outcome of the studies 
The general outcome of each study was derived from the conclusions drawn by 
the authors. A study was judged positive when the authors concluded that ero-
moglycate was more effective than placebo. A study was classified as "equal" 
when the authors reported no difference between the treatments, No studies in 
favour of placebo treatment were found. The methods and conclusions of the 
different trials were summarized and tabulated. 
Statistical pooling 
For each study the 95% confidence interval (CI) for the difference in symptom 
score between placebo and cromoglycate treatment was calculated, separately 
for "wheeze" and "cough", If no separate scores were available we used the 
score for" daily symptoms". In case the published data were not sufficient to 
compute a 95% CI and the trial was published not more than 5 years ago, we 
sent a request for data to the authors. If, apart from the statement "not signifi-
cant" I no exact p-value was given we calculated the effect of two extreme alter-
natives (p=O.l 0 and p=0.90). Most studies used a scale of 0-3 points; in case a 
different scale was used it was transformed for our purposes. We computed the 
pooled estimates of the treatment effect and the pooled 95% CI and tested the 
hypothesis of homogeneity." In case of heterogeneity the pooled confidence 
interval was computed taking heterogeneity into account" and the correspond-
ing tolerance intervaL" In order to explain heterogeneity the influence of study 
characteristics on the outcome was evaluated by means of univariate and multi-
variate regression analysis (observations weighted by the reciprocal of the square 
of the standard error of the mean difference between placebo and SCG). The 
influence of asthma severity of the study population (expressed in the mean pla-
cebo score) on the outcome was evaluated by means of functional relation-
ships.19 To further explore heterogeneity a funnel plot was made of the effect 
estimate against the precision 20, for all trials. The precision of a trial was defined 
as l/standard error. The symmetry of the funnel plot was tested." 
To show the relative difference in treatment effect, for each study the relative 
improvement in mean (RIM) (= percentage improvement compared to placebo) 
was calculated: 22 
RIM = (mean score Iplacebo) - mean score Isec)) , 100/ mean score Iplacebo) 
A similar pooling and testing for homogeneity, as described above, was per-
formed; for this procedure a first order approximation was used as an estimate of 
the standard error of the RIM. 
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Results 
Studies 
A total of 251 articles was identified in Medline of which 17 met our inclusion 
criteria.,,"39 Embase provided one additional trial" and two additional trials were 
provided by the database of the pharmaceutical company.40·41 The Cochrane 
Controlled Trial Register did not supply further trials, but two more trials were 
found by searching the references of relevant articles."·43 The excluded studies 
were either not double-blind, not randomised, not controlled, did not concern 
the appropriate age group, or investigated the effectiveness of SCG on exercise-
induced asthma; one double blind cross-over study was excluded because the 
results were only partially presented.44 Finally, 22 randomised controlled trials 
(RCTs) of SCG as prophylactic agent in children with asthma were reviewed. The 
characteristics of the included trials are presented in Table 2; the studies were 
European (n=15, of which 9 were British) and North American (n=7). Studies dif-
fered in design, severity of asthma, number of children included, age of children, 
administration of medication, follow-up period, and year of publication. In total, 
900 children were studied in the 22 trials, with sample size ranging from 9 to 218 
children; 480 children (11 trials) were of preschool age and 420 were 5 years or 
older (11 trials). Prior to 1977, studies included only children aged 5 years and 
over. The median duration of intervention was 4 weeks (range: 3 - 26 weeks). All 
studies included children with moderate to severe asthma, and all but one study 
were hospital-based. In nine papers it was unclear whether the population was 
hospitalised or ambulatory, nor was it clear whether and what concurrent medi-
cation was permitted during the triaI. 24 ,26,31,34,36,38.4o Only one trial selected chil-
dren with moderate asthma through general practitioners. 16 Compliance was 
discussed in only four papers.16,23.24.28 
Sid e-effects 
Thirteen RCTs reported side effects, all these were minor and the incidence was 
low. Cough was most often reported, followed by bitter taste, wheeze, sneeze, 
throat irritation and perioral eczema. Some studies did not specify the kind of 
adverse effects but merely stated 'minor'. 
Outcome 
In 15 studies a positive outcome was concluded, and 2 studies were partially 
positive, depending on age" and symptom.39 Five RCTs had an equal outcome. 
We disagreed with the positive conclusion of three of the studies. First, the con-
clusion by Fox and colleagues34 that SCG is beneficial was based on three as-
sessments (clinical assessment, (parental) symptom score and FEV,). All three 
assessments were available in only 22 children of the 28 children included in the 
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Table 2 
Randomised controlled trials evalualing the effectiveness of inhaled sodium cromoglycate (SCG) in children 
Additio- No.of Duration 
Reference Setting Design Dose SCG nat study Inclusion criteria Age patients. . Major effect Side effects Authors' Review (yrs) includedl mt~rventlon parameters conclusion score 
arm analysed penod(s) 
Smith school cross-over 4dd20m9 none Longstanding perennial asthma 5-16 51/44 2x4 weeks daily symptom scores cough positive 44/91 
et al.41 health Spin haler lungfunction (0.48) 
(1968) seN'lce additional medication 
laboratory 
Hyde not specified cross-over 4dd20m9 none duration of asthma> 1 year 6-16 60/57 2 x 3 weeks daily symptom scores irritated throat, positive 43/91 
et al.38 Spinhaler definite symptoms before clinical assessment headache, (0.47) 
(1970) inclusion lung function cough, 
additional treatment wheeze 
Sly~ outpatients cross-over 4dd20mg none asthmatic, responded on exercise 6-12 21/16 2x 4 weeks daily symptom scores sore throat positive! 38/94 
(1970) Spinhaler with bronchospasm dinkal assessment equal (OAO) 
lung function 
lab tests, X~ray, 
additional treatment 
Collins et al.36 out~ and cross-over 4dd20m9 none severe allergic asthma, wheezed 7-17 63/63 2 x4 weeks daily symptom scores cough. dry positive 39/94 
(1971) inpatients TurtJuhaler at least once a week clinical assessment mouth, (0.41) 
lung function dizziness 
nausea, 
headache 
limburg 37 inpatients cross~over 4dd20mg none in asthma centre 6-16 30/29 2 x 4 weeks daily symptom scores cough positive 45/94 
(1971) Spinhaler and regular asthma symptoms lung function (0.48) 
additional treatment 
Fox et al.34 hospital cross~over 4dd20mg none chronic severe perennial 5-16 23 2 x12 weeks: daily symptom scores, cough positive 32191 
(1972) Spinhaler bronchial asthma, a period of treatment clinical assessent, (0.35) 
observaflon in the cliniC for at lung function 
least one year and pulmonary 
function impairment 
Table 2 - continued 
Additio· No.of Duration 
Reference Setting Design Dose SCG nal study Inclusion criteria Age patients. . Major effect Side effects Authors' Review ( ). I d dl interventIon parameters conclusion score 
arm yrs ~nnCa~S~d period(s) 
Silverman et outpatients parallel 4dd20mg none perennial asthma and disabillty 7-9 53 2 weeks: daily symptom scores, cough, dry positive 39/92 
al.~ (1972) capsules exceeding 6-8 wks in preceding baseline clinical assesment, throat (0.42) 
year, or 3-4 wks in preceding 3 8 weeks: lung function 
months despite of regular treatment 
bronchodilator therapy, never use 
of corticosteroids or cromoglycate 
Hyde et al.33 hospital cross-over 4dd20mg none chronic disabling asthma 5-16 38 4 weeks: additional treatment, cough, throat positive 38/87 
(1973) Spinhaler baseline clinical assessent, pain, dizzy (044) 
2x4 weeks: lung function 
treatment 
Crisp unspecified cross-over 4dd20mg none chronic asthma and 2 out of: 5-17 40/40 2 x 4 weeks dally symptom scores rash, wheeze positive 45/87 
etal.32 small device nearly daily symptoms; nearly clinical assessment (0.52) 
(1974) daily medication needed; lung function 
intermittent or long term steroid additional medication 
usage 
Hiller unspeciefied cross-over 4dd20mg beta- chronic perennial asthma, 9-13 11/9 4 x 1 month daily symptom score none positive 44/87 
etal.31 factorial Spinhaler metha- symptoms inadequately controlled clinical assessment (0.51) 
(1975) sone 17 by scg and bronchodilators additional medication 
valerate 
Hitler hospital cross-over 3dd20mg none frequent troublesome asthma 2-4 17 1 week: daily symptom scores, unspecified positive 34/87 
et al.2g nebulised baseline clinical assessent, (0.39) 
(1977) 2x4 weeks: lung function 
treatment 
Matthew 30 outpatients cross-over 4dd20mg none severe chronic perennial asthma 3-6 9 8 weeks: daily symptom scores, unspecified positive 29/87 
(1977) nebulised + symptoms in baseline period baseline additional treatment, (0.33) 
2x4 weeks: lung function 
treatment 
Edmunds unspecified cross-over 4dd 1 slow- perennial asthma 5-15 30/30 3 x 4 weeks daily symptom scores, nausea, positive 29191 
et al.28 capsule release lung function, additional vomiting, (033) 
(1980) amino- medication abd. pain, 
phylline headache 
Glass etalP hospital cross-over 4dd20mg Theo- control of asthma was poor under 1-4 16 4 weeks: daily symptom scores, minor equal 29/94 
(1981) nebulised phylline routine treatment baseline additional treatment (0.31) 
syrup 4 3x8 weeks: 
dd, to treatment 
body 
weight 
Geller- hospital cross-over 4dd2ml none frequent troublesome wheezy 0-2 44 2 weeks: daily symptom scores, unspecified equal! 34/94 
Bernstein nebulised bronchitis despite regular baseline clinical assessent positive (036) 
et al.26 bronchodilator therapy + 2x4 weeks: 
(1982) symptoms ·In baseline period treatment 
Miraglia del hospital cross-over 3dd20mg none perennial asthma and symptoms 0-5 31 2 weeks: daily symptom scores, cough, sneeze positive 35/91 
Giudice nebulised despite bronchodilator therapy baseline additional treatment, (0.38) 
et al. 4O 2x4 weeks: cl"lnlcal assesment 
(1982) treatment 
Henry hospital cross-over 3dd20mg ipratro- suffered from recurrent attacks of <2 20 2 weeks: daily symptom scores, unspecified equal 23194 
et al.25 nebuJised plum wheezing and considered baseline additional treatment, (0.24) 
(1984) bromide troublesome asthma by 3x8 weeks: lung function 
3 dd pediatrician and parents treatment 
2501\l 
Cogswell hospital cross-over 4dd20mg none regular attacks of asthma that 1-4 24 4 weeks: daily symptom scores, unspecified positive 43/91 
et aJ.24 nebulised required at least one admission to baseline additional treatment (0.47) 
(1985) hospital 2x26 weeks: 
treatment 
Bertelsen hospital parallel 3dd20mg none recurrent wheezy bronchitis 1-4 54 4-8 weeks: daily symptom scores, cough,wheeze equal 31195 
et al.43 nebulised demanding therapy at least once baseline additional treatment and eczema (033) 
(1986) a month during preceding winter 10 weeks: 
or later treatment 
rable 2 - continued 
Additio- No.of Duration Age patients. . Major effect Authors' Review Reference Setting Design Dose SCG nal study Inclusion criteria ( )' I d dl mterventlon Side effects parameters conclusion score 
arm yrs ~nnCa~S~d period(s) 
Yuksel hospital cross-ever 4dd5mg none preterm born, wheeze andlor 0-2 16 2-3 weeks; daily symptom scores, unspecified positive 32191 
etal.42 coffeecup cough 3-4 days/week for the treatment additional treatment, (0.35) 
(1992) previous 4 weeks + sypmtoms for lung function 
at least 3 days following all 
respiratory tract infections 
Furfaro outpatients parallel 3dd40mg none presence of chronic pulmonary 0-1 31 3 weeks: daily symptom scores, unspecified equal 56195 
etaP3 nebullsed symptoms for at least one month baseline lung function (0.59) 
(1994) and wheezing documented by a 6 weeks: 
physician + symptoms in baseline treatment 
period 
Tasche general parallel 3 dd 10 mg none previously been prescribed anti~ 1-4 218 4 weeks: daily symptom scores, eczema in equal 75195 
et al.15 practice Spacer- asthma medication and meeting baseline loss of participants, mask area, (0.79) 
(1997) setting device + formulated criteria for moderate 22 weeks: additional medicatlon cough 
facemask asthma treatment 
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study. They consider it of practical importance that 14 children showed im-
provement based on at least one of the assessments; we question this positive 
conclusion. The second study in which we disagreed with the authors was the 
crossover study by Hiller et al. 29 Their conclusion that SCG was beneficial in 11 
of 17 children was based on the opinion of the parents. Symptom scores for 
cough changed significantly in favour of the SCG group, symptom scores for 
wheeze did not Four children required one or more short courses of steroids 
during the follow-up period of four weeks. Moreover, it is unclear during which 
type of treatment the rescue medication was given. Finally, Collins-Williams et 
al." found a significant improvement after SCG treatment in (only) four out of 
nine symptoms, yet concluded that the treatment was useful. 
Methodological assessment 
The results of the methodological assessment are given in Table 3; the decision 
of the third reviewer was necessary for one article.34 The methodological scores 
ranged from 24% - 79%; the mean score of 43% indicated mediocre methodol-
ogy. The most prevalent methodological shortcomings were in the areas of com-
pliance (a mean of only 8% of the maximum attainable score on this item for all 
studies), selection and inclusion (23%) and statistics and analysis (28%). The 
mean scores for the description of blinding and intervention were relatively 
good; 66% and 64% respectively; however, the ranges of these proportions are 
large. Twelve studies were published before 1980. The mean method score for 
these latter studies was 43% (range 33-52%) versus 42% (range 24-79%) for the 
10 trials reported after 1980. Our own recent study scored highest; to control for 
reviewers'-review bia~, the independent observer re-evaluated our study, which 
resulted in similar scores. 
Statistical pooling 
For most studies the data were insufficient to allow a formal meta-analysis with 
odds ratios. Figure 1 presents two graphs of 95% Cis of differences in mean 
symptom score (placebo minus SCG) for each study. The Cis are ordered accord-
ing to year of publication of the study. In seven studies the Cis were calculated 
using the separate symptom score of "wheeze" and "cough", in 11 studies we 
used" day symptoms". In two studies"·39 only the results for" cough" were pre-
sented; data on Ilwheeze" were not published because the difference in treat-
ment effect between placebo and SCG was not significant. 
The chi-square test rejected the hypothesis of homogeneity of the study results 
(p<0.005), both for the absolute and the relative outcome measures. This hetero-
geneity could be due to the year of publication of the trial, the study design (par-
allel/cross-over), age of the children, placebo symptom level (i.e. severity of 
asthma), method of administration of the medication, duration of follow-up, fre-
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Table 3 
Methodological quality of RCTs evaluating the effectiveness of inhaled sodium cromoglycate in children. 
Reference A B C D E F G H method melhod authors' 
score* score % conclusion 
maximum score 6 13 23 6 7 6 24 10 95 
Smilh el al." (1968) 4 19 6 3 8 2 44/91 48 positive 
Hyde et al." (1970) 4 20 6 2 0 4 6 43/91 47 positive 
Sly 39 (1970) 0 4 13 5 3 0 7 6 38/94 40 positive/equal 
Collins et al." (1971) 2 7 18 6 0 0 3 3 39/94 41 positive 
limburg 37 (1971) 4 13 5 3 0 11 8 45/94 48 positive 
Fox et al." (1972) 5 14 6 0 0 2 5 32/91 35 positive 
Silverman et aL35 (1972) 3 7 16 0 8 3 39/92 42 positive 
Hyde el al. 33 (1973) 6 13 4 3 0 6 5 38/87 44 positive 
Crisp et al.33 (1974) 3 6 17 6 3 0 8 2 45/87 52 positive 
Hiller et al.33 (1975) 2 10 18 4 3 0 5 2 44/87 51 positive 
Hiller el al." (1977) 0 10 14 4 3 0 2 1 34/87 39 positive 
Matthew 30 (1977) 0 4 13 4 3 0 3 2 29/87 33 positive 
Edmunds et al." (1980) 0 4 14 0 2 6 2 29/91 33 positive 
Glasselal." (1981) 0 4 14 2 0 1 6 2 29/94 31 equal 
Geller-Bernstein et al. 26 (1982) 4 16 2 3 0 6 2 34/94 36 positive/equal 
Miraglia del Giudice el al.<o (1982) 1 4 14 3 3 0 7 3 35/91 38 positive 
Henry et al." (1984) 0 0 16 3 0 0 2 2 23/94 24 equal 
Cogswell et al." (1985) 10 13 4 3 1 9 2 43/91 47 positive 
Berlelsen el al." (1986) 1 3 12 3 3 0 6 3 31/95 33 equal 
Yuksel el al." (1992) 3 4 13 3 1 0 5 3 32/91 35 positive 
Furfaro et al.23 (1994) 3 13 13 5 4 3 11 4 56/95 59 equal 
Tasche et al.16 (1997) 6 11 20 3 6 3 21 5 75/95 79 equal 
percent score per item mean 23 45 66 64 33 8 28 35 43 
range 0-100 0-100 52-87 0-100 0-86 0-50 8-88 10-80 24-79 
* Denominator reduced for crossover studies and for non applicable items (see text) 
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Figure 1 
95% confidence intervals of absolute difference for symptoms 
quency of dosage, methodological score, and other study characteristics. Only 
year of publication, age of the children, and study design were significant predic-
tors of outcome in the univariate regression analysis. The multivariate regression 
analysis showed that only year of publication and study design were significant 
predictors of the effect size: older cross-over studies were more likely to produce 
a positive effect of SCG treatment. Age of the children, which was highly corre-
lated with year of publication (,lP0.83), was not significant in this analysis. There 
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Figure 2 
95% confidence intervals of relative difference for symptoms. 
was a linear relation between treatment effect and control level (slope 0.96 
(SE:O.08); intercept -0.13 (SE:0.05). The conclusion of this analysis is that hetero-
geneity cannot be explained by asthma severity, and transformation of the data 
into RIM does not change the conclusion of heterogeneity. 
The pooled 95% Cis under the assumption of heterogeneity and the correspond-
ing tolerance interval are shown in Figures 1 and 2. The latter includes zero, both 
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Funnel plot for effect size (delta) versus precision (l/standard error) of selected trials. 
for the absolute treatment effect and for the relative treatment effect. The funnel 
plot is shown in Figure 3; the hypothesis of symmetry was rejected (p=O.028). 
The asymmetric funnel shows that small studies with negative or equal outcomes 
are underrepresented. 
Discussion 
This review shows that no firm conclusions can be drawn on the therapeutic ef~ 
feet of SCG compared to placebo. In the statistical pooling of the trial results we 
computed the 95% CI assuming heterogeneity and the 95% tolerance interval 
because the test on homogeneity was rejected. The latter interval included zero, 
indicating that the outcome of future studies cannot be predicted." 
Study characteristics 
Although SCG was indicated as treatment for mild to moderate asthma, nearly all 
trials comprised hospital~based populations of children with moderate to severe 
asthma. Nine studies administered the medication by nebulisation. Nowadays, 
spacer devices are available for young children, which are less time~consuming 
and less tedious than nebulisers, particularly at home. Metered dose inhalers with 
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spacer devices were used in only two studies. 16.42 Spinhalers were used in 11 
trials with older children. The way of administration, a critical factor in dose de-
livered to the lungs, was not a predictor of outcome. Diagnosis and measure-
ment of asthma in young children is difficult 45.46 and age effects might reduce or 
mask the effects of sodium cromoglycate. However, this is unlikely: although 
children's age was a significant predictor for treatment effect in the univariate 
analysis, the multivariate analysis showed that publication date of the trial was a 
confounder for age of the children. Follow-up duration in 14 trials did not exceed 
4 weeks, which, according to guidelines, may be too short to assess treatment 
effect. Although duration of follow-up was not a predictor of outcome, it was 
notable that none of these short-term trials had an 'equal' conclusion (12 were 
positive and 2 were positive/equal). In 7 studies the authors tried to find charac-
teristics or criteria to predict which children would respond to cromoglycate; 
however, none were found 16,2'1.2 5,34,35,37,43 Silverman et al. 35 reported that only the 
acute protective effect of SCG in exercise tests predicted the probable success or 
failure of long-term treatment with the drug. 
Earlier reviews 
The effects of treatment with SCG have been reviewed earlier. Edwards" exam-
ined the evidence for the anti-inflammatory action of cromoglycate in adults and 
children; he discussed a large number of controlled and uncontrolled studies but 
it is unclear how these were selected. Hoag and McFadden" summarized stud-
ies on the effect of cromoglycate on bronchial hyperreactivity in adults and chil-
dren. The review by Schweitzer and Brossier Ballano" discussed three controlled 
studies assessing the efficacy of cromoglycate in children aged 2 years and 
younger. Finally, Holgate'O reviewed recent trials with metered dose inhalers in 
children and adults and discussed challenge studies, therapeutic studies and long 
term effects of SCG. None of the earlier reviews were systematic, assessed the 
methodologic quality or tried to quantify treatment effects. 
Methodological assessment 
Meta-analysis and scores related to drug therapy have been criticised, but are 
increasingly popular, because they give insight in the combined results of trials 
and provide data for rational decision making. 51 ,52 A review of scales and check-
lists for assessing the quality of randomised controlled trials shows limitations in 
virtually every scale.'4 We decided to use the items proposed by Chalmers15 be-
cause they address the methodology and the presentation of the study exten-
sively. However, we found shortcomings while using the scale, including the lack 
of attention for sample size, protocol violations and permitted concurrent medi-
cation. 
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The methodological quality of the RCTs reviewed here was poor, as demon~ 
strated by the mean score of 43% of the maximum attainable score. We have to 
take into account that 12 studies were published prior to 1980; informed con~ 
sent, clear description of inclusion criteria, rejection logs and baseline characteris-
tics, adequate sample size calculation, calculation of confidence intervals, and 
regression analysis were not common practice at that time. 
Statistical pooling 
The estimates of the differences between placebo treatment and cromoglycate 
treatment for symptom scores of "cough" and "wheeze" (under assumption of 
homogeneity) were 0.16 and 0.10, respectively. This is suggestive of a small 
therapeutic effect of cromoglycate. We doubt whether this is of clinical rele-
vance. On the other hand, the overall relative improvement estimates were 18% 
and 24%, respectively. This high relative improvement combined with the minor 
absolute improvement shows that, overall, the severity of symptoms under pla-
cebo treatment was low. Indeed, although most studies in our review included 
children with severe asthma, the mean daily symptom score in the placebo 
groups was low (0.8). This is mainly due to a dilution by symptom free days, a 
common finding in trials of childhood asthma. 53•54 
One should be cautious about drawing definitive conclusions concerning the 
role of sodium cromoglycate in the treatment of asthma in children on the basis 
of this review for several reasons. Medical literature can be misleading as a result 
of selective submission and publication of RCTs showing a statistically significant 
treatment effect.55 Year of publication of the study proved to be the most signifi-
cant predictor of treatment effect and the asymmetric shape of the funnel plot 
suggests bias: studies with a positive treatment effect had relatively little precision 
and most were performed before 1980. An explanation might be that attention 
for publication bias started around 1980.55,56 The trials were heterogeneous in 
their treatment effects. Refraining from pooling has been a serious option con-
sidering the heterogeneity and the publication bias. 57 Nevertheless, we calculated 
the pooled confidence intervals and the tolerance interval as useful summary 
measures. In two trials36.39 the results for "wheeze" were not published because 
the difference between placebo and cromoglycate was not significant. This could 
result in some bias in favour of SCG in the "wheeze" calculation. On the other 
hand, two trials 32,33 with positive outcomes were omitted from the pooling be-
cause the published data were insufficient. The results of the statistical pooling 
were based on symptoms only, because symptom scores were available in all 
trials. We did not include studies on the immediate effects of SCG on exercise-
induced asthma. This is a different issue, not pertaining to the use of SCG as ad-
vised by current guidelines. Finally, we did not include studies on the effects of 
combined therapy, i.e. the corticosteroid-sparing effects of cromoglycate. 
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Conclusion 
We conclude that, on the basis of published randomised trials, the superiority of 
SCG over placebo in the maintenance treatment of asthmatic children has not 
been proven. Therefore, we consider it is justified to recommend SCG no longer 
as a first-line prophylactic agent in childhood asthma. 
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Appendix 1 
Operationalisation of the criteria for methodological assessment of ran-
domised controlled trials according to Chalmers 15 
A Selection description (3 points). Number of patients seen and reject log (3 
points). 
B Randomisation blinding, method of random blinding (10 points). Testing ran-
domization (3 points). 
C Blinding of patients (8 points). Blinding of physicians re therapy (8 points). 
Blinding of physicians and patients re results (4 points), testing blinding (3 
points). 
o Therapeutic regimens definition (3 points). Control regimen (placebo) ap-
pearance (1.5 points). Control regimen taste (1.5 points). 
E List of withdrawals (3 points). Handling of withdrawals in analysis (4 points). 
F Testing compliance (3 points). Biological equivalent (3 points). 
G Prior estimates of numbers (endpoints selected, difference of clinic interest a 
and ~ estimated) (3 points). Test statistic and observed probability value are 
stated (3 points). Posterior ~ estimates of observed difference for negative 
trials mentioned (3 points). Confidence limits (2 points). Life-table or time 
series analysis shown (2 points). Regression analysis correlation (2 points). 
Appropriate statistical analysis (4 points). Statistical discussion side effects (3 
points). Blinding statistician or analyst re results (2 points). 
H Dates of starting and stopping accession (2 points). Results of pre-
randomisation: data analysis, prognostic favouring (2 points, in crossover 
studies 1 point). Tabulation of events employed as endpoint for each treat-
ment (2 points). Timing of events (4 points). 
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Discussion, conclusions and suggestions for further research 
The main aim of this thesis was to investigate the feasibility of long-term inha-lation therapy and the effectiveness of sodium cromoglycate, in young chil-
dren in a general practice setting. To achieve this aim we conducted a small 
study of searching strategies in the computerised files of general practitioners, a 
randomised placebo-controlled trial in primary care and a systematic review on 
sodium cromoglycate. The feasibility of inhalation therapy was further discussed 
in a separate chapter, and a follow-up study eight months after finishing the trial 
was done. We now discuss the major findings along the lines of the research 
questions formulated in chapter one, and give suggestions for further research. 
Feasibility of prophylactic inhalation therapy in 
young children 
In our five-month study (chapter three), patient compliance was relatively high, 
even with an intensive daily regimen and a drug that turned out to be not more 
effective than placebo. Compliance was probably high because of the home-
based trial setting and our intensive monitoring through home visits. It is a well-
known fact that compliance in daily practice will always be lower than in a 
closely supervised trial situation. Moreover, in the recruitment phase prior to the 
inclusion a selection of children and parents had taken place; parents who fore-
saw feasibility problems did not start the trial. Although our findings show that in 
young children long-term inhalation treatment is feasible in the home situation, 
physicians should be aware that a considerable proportion of the parents are 
reluctant to start, or will discontinue, long-term prophylactic inhalation therapy. 
Compliance of prophylactic treatment showed a relation with current symptoms 
(chapter five), suggesting that parents of young children with moderate asthma 
who are confronted with their child's symptoms will become more compliant in 
administering prophylactic medication to their child. Timely, intermittent short 
treatment with anti-inflammatory drugs for episodes of moderate asthma in 
young children might possibly be beneficial and more feasible. Wilson and Sil-
verman investigated the effects of high-dose inhaled steroids at home for acute, 
episodic asthma in preschool children recruited from a hospital population.' They 
concluded that this treatment was beneficial in modifying the severity of the 
attacks, although the results were influenced by hospital admission and oral cor-
ticosteroid treatment. This kind of application might be promising and has so far 
never been investigated in young children with mild and moderate asthmatic 
symptoms in general practice. 
In national and international guidelines, inhalation therapy is recommended as 
the preferred way to administer anti-asthmatic drugs to young children.,,3 Oral 
anti-asthmatic drugs are often prescribed for children who might be able to use 
an inhaler effectively."s Many physicians and/or parents apparently still prefer 
87 
Chapter eight 
non-inhalation therapy in this young age group. Therefore, it is very interesting to 
explore the effectivity, safety and compliance of anti-asthma drugs that can be 
given by means other than inhalation. The first and most accepted route is the 
oral one. The first candidate for this route of administration are the oral anti-Ieu-
kotrienes that seems worthwhile to investigate in this age group.' Second, oral 
salbutamol versus inhaled salbutamol in transient episodes of wheezing in young 
children has never been investigated in general practice. Third, deptropine, an 
anti-cholinergic, is often prescribed in the Netherlands for young children with 
asthmatic symptoms,5 but has not been studied in a trial comparing the drug with 
placebo or an alternative drug. A second route of administration might be nasal; 
nasal administration of anti-inflammatory drugs rarely has been investigated for 
their effects on asthma. When given for rhinitis, they often show beneficial effects 
on respiratory symptoms in preschool', school-age children 8, and adults9, but this 
has not yet been demonstrated in a clinical trial focussing on children with 
asthma. 
For symptom relief, without prophylactic aims, short-acting bronchodilators are 
recommended. Long-acting beta-mimetics are not indicated for this purpose, 
mainly because of the fear of masking symptoms, thus introducing a risk for delay 
in starting anti-inflammatory prophylactic treatment. Now that we are aware of 
this risk, preschool children with mild and moderate asthma can perhaps be 
adequately treated with long-acting bronchodilators. It might be sensible to ex-
plore this theory in a properly designed trial. 
Effects of inhalation therapy with sodium 
cromoglycate 
In national and international guidelines prophylactic therapy is recommended in 
an early stage of the disease.2•3 Recently, sodium cromoglycate and inhaled ster-
oids were both advocated as drugs of first choice for preventive treatment of 
moderate asthma, rather than recommending use of cromoglycate before in-
haled steroids. Until our study, the effectiveness of cromoglycate was never in-
vestigated in a placebo-controlled trial in young children with moderate asthma 
in general practice. In addition to such a trial, we performed a systematic review 
of clinical trials with sodium cromoglycate published up to 1998. 
In our trial, children in both the cromoglycate group and the placebo group im-
proved significantly during the trial period. This finding could be explained by a 
placebo effect, natural course of the disease and the personal supervision associ-
ated with a clinical trial, as found previously in many trials on asthma in children. 
No differences in any outcome measure were found and no serious side effects 
were reported for either of the groups by parents or general practitioners. 
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Our trial showed no benefit of sodium cromoglycate. Several explanations can 
be addressed that might explain the negative finding, namely: the selection of 
children with (moderate) asthma, the dose of cromoglycate prescribed, the 
spacer device with face-mask and drug delivery to the lungs, subjective symp-
toms as outcome measure, the length of follow-up and the statistical power of 
the trial. Each item will be discussed. 
Moderate asthma 
It is possible that we selected children with asthma as well as children with tran-
sient wheezing. The uncertainty of labelling recurrent and chronic respiratory 
symptoms in young children as 'asthma' is discussed in chapter one. It is difficult 
to distinguish between 'asthma' and 'wheezing' in preschool children, hence 
these are combined under the label 'asthma' in this age group. Since cromogly-
cate is recommended for mild and moderate asthma and these children are 
mainly treated by their general practitioner'o, we selected children from general 
practices to investigate appropriate patients. The severity of asthma was classified 
according to current guidelines, based on symptoms and medication used, be-
cause objective outcome measures are not available in the home situation. The 
children classified as having moderate asthma had a prescription of an anti-
asthma drug in the past, and had actual symptoms and/or medication. The chil-
dren on maintenance treatment with inhaled steroids were classified as having 
severe asthma and were therefore excluded. The children with moderate asthma 
who started the trial had symptoms on 48% of the days in the baseline period, 
hence preventive treatment was indicated. If the therapeutic effect of sodium 
cromoglycate in our trial had been diluted by transient wheezers (non-asthmat-
ics), we would have expected to find some influence of patient characteristics 
like atopy, parents with a positive asthma history or siblings with respiratory 
problems, since these characteristics are associated with higher risk of asthma in 
the future. Proponents of sodium cromoglycate assume that it is effective in 'al-
lergic asthma'; however, we have never found a definition of allergic asthma, nor 
studies in children that showed atopy or allergies as predictors of success of 
treatment with cromoglycate. An indication for a confining role of atopy in the 
effectivity of cromoglycate was concluded by Edwards, who found some evi-
dence of greater efficacy when sputum eosinophilia was present. 1! However, in 
the review by Hoag and McFadden, atopy did not influence the overall outcome 
of sodium cromoglycate treatment. 12 
Dose prescribed 
A three times daily dose was chosen in our protocol because this regimen was 
considered suitable in the daily program of families with young children. In the 
Netherlands a four times daily dose is recommended in children and adults,13 but 
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in the UK sodium cromoglycate is recommended three times daily.3 The reason 
for this difference in recommendations is not clear. 
Spacer device and dose delivered 
How much of the medication actually reached the lungs of the children is un-
known, but this does not invalidate the conclusions about treatment as advised in 
guidelines and as it is commonly practised. It is well known that only a small pro-
portion of the drug sprayed into a spacer device actually reaches the lungs and 
that the variation between spacer devices can be large, and relatively unfavour-
able for the Aerochamber®. Nevertheless, using a spacer device is the preferred 
way to administer inhalation medication to young children and effectivity of sal-
butamol, administered with an Aerochamber®, has been demonstrated. 14•1S The 
amount of salbutamol delivered from spacer devices was similar to the amount 
of sodium cromoglycate. 16 In addition to that, both Comis and Novembre and 
their colleagues have shown that 10 mg cromoglycate, given by Nebuhaler® and 
Volumatic®, respectively, is effective in the prevention of exercise-induced 
asthma in school-aged children. 17•18 Because the size of the spacer is probably 
less important in young children ", it is unlikely that the use of an Aerochamber® 
contributes importantly to the negative outcome of our study. 
Subjective outcome measure 
As was the case in diagnosing asthma, symptoms were the main outcome meas-
ures for effectiveness. Validated symptom assessments in research of childhood 
asthma are lacking. The influence of symptom perception of the parents on re-
cordings of symptom assessments is expected to be large. Tools to adjust for in-
fluences like this are unknown. Being aware of this limitation, an overall symptom 
measurement should include the frequency, duration and magnitude of symp-
toms." Beside the proportion of symptom-free days, several other outcome 
measures from the parental symptom score lists as well as from the interview at 
the monthly home visits, were analysed in our study. It is debatable whether 
other, more objective, measures of morbidity would be superior to symptoms, 
since the latter are directly related to the burden of the disease. 
Beside the fact that symptom-scoring systems for use in young children are not 
validated against objective parameters of disability, none has been validated for 
objective measures of airflow obstruction. Development of portable equipment, 
which enables airway function to be measured with a mouthpiece or a facemask 
while the child is breathing normally, might be a useful clinical tool. Such a pro-
cedure should be easy and applicable in the home situation. Standardisation of 
the technique is ongoing,21 
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Treatment period 
In general it is recommended to use sodium cromoglycate for a period of six 
weeks before deciding whether it is effective or not. The follow-up period of our 
trial was five months and outcome measures were based on months 2-5 of the 
intervention period. There was no time-treatment interaction. In our systematic 
review of all published placebo-controlled trials in children with asthma (chapter 
seven), half of the trials (n~11) investigated preschool children; five trials showed 
benefit of cromoglycate, five showed equal results and one trial was partly posi-
tive, partly equal. Although duration of treatment periods was not a predictor of 
outcome in all trials, it was noteworthy that only one of the positive trials among 
preschool children had a treatment period of more than four weeks. In a review 
of (non-placebo controlled) studies investigating the effect of inhaled sodium 
cromoglycate on bronchial hyperresponsiveness in asthmatic children and adults, 
less reduction was shown in studies conducted for six weeks or less. 12 
Power 
Enough children were included to prove our negative finding. In case the trial 
treatment had resulted in a 20% symptom reduction, we would have had a 98% 
chance to confirm this, given our sample size. Such a statistical power is rarely 
reached in clinical trials. 
In conclusion, there seems to be little reason to doubt the negative result of our 
trial showing that children 1-4 years old will not benefit from prophylactic inhala-
tion therapy with cromoglycate via the Aerochamber@ 
We conclude from our trial and review on sodium cromoglycate that the place 
for this drug in the therapeutic arsenal of long-term prophylactics for asthmatic 
children has been overvalued. Through history, it seems that sodium cromogly-
cate has achieved an eminent place in anti-asthma prophylaxis in children, mainly 
because of research in open trials, crossover studies published before 1980 and 
in studies of the immediate effects on exercise induced asthma, but not based on 
evidence from more recent placebo-controlled trials. In our systematic review we 
did not include studies on the immediate effects of cromoglycate on exercise-
induced asthma or studies on the effects of combined therapy like the cortico-
steroid sparing effects of cromoglycate, considering these regimens not to per-
tain to the use of sodium cromoglycate as advised by current guidelines for chil-
dren of all ages. 
Conducting a clinical trial in general practice 
Failure of trials is mostly caused by disappointing practical and organisational 
aspects. The successful development of our trial can mainly be attributed to the 
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fact that the researchers were independent of the participating general practitio-
ners and were in charge of most of the practical aspects of the trial organisation 
like enrolment and approaching the patients, data collection and follow-up. 
Computerisation of the medical records of patients in general practice offers an 
easy way to select patients for research. Since, in our case, children with asthma 
could be selected from data on specific treatment, enrolment from the computer-
ised medical records of the general practitioners was possible. Research concern-
ing prevalent diseases could enrol patients by searching medical records on di-
agnoses, specific medication or symptoms. In a trial that requires patients with 
incident illness, a preliminary selection like ours would not be possible and re-
searchers would be dependent on general practitioners for enrolment of their 
patients. Nevertheless, even in trials on recurrent incident illnesses or complaints, 
the computer can help by indicating to the general practitioner that this might be 
an eligible patient for the trial. A subsequent screen could show telephone num-
bers of the research team, questions for initial data collection or informed con-
sent and by 'on-line communication' the researchers could be contacted and 
take over further selection, inclusion and data collection. 
Though time consuming, the direct patient contacts were another advantage of 
our trial setting. Home visits by the researchers instead of hospital visits by the 
patients (possibly parents with young children) have minimised the number of 
patients lost to follow-up. Collecting data from patients probably works best 
without interposition of caregivers. Computer technology can also be important 
in data collection. In 1998, 9% of the overall Dutch population possessed an 
Internet connection, this number has increased by 43% in the last year." It is 
feasible that patients could e-mail their daily symptoms, questionnaires or meas-
urement scores (from own computers or from handheld computers distributed 
by the researchers) to a main trial computer or enter them on a secured site. 
Even voice response units 'calling' patients at agreed times and collecting the 
data in files that are ready to be analysed, can be envisaged. 
Because computerisation in Dutch general practices is much more developed 
than in hospitals, and information and communication technology continue to 
develop, we expect that research in general practice will become increasingly 
accessible and continue to expand. 
Determinants of children who continued using 
inhaled prophylactic treatment 
In chapter six, predictors for use of prophylactic inhalation treatment eight 
months after the trial were found in patient characteristics obtained by history 
taking and differences in morbidity during the trial. Realising that 'use' of inhaled 
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prophylactic therapy at follow-up can not be directly translated into 'need' for 
this treatment, most of the significant characteristics in our short-term follow-up 
correspond with predictors for future asthma in cohorts that are followed at 
larger intervals.2J.25 Several characteristics, that are easily obtained by history tak-
ing, may help physicians who care for young children with asthma: they can pre-
dict which children will 'need' prophylactic inhalation therapy for a longer period. 
To close the final chapter of this thesis it can be concluded that 
• prophylactic inhalation therapy in children under the age of four years is feasi-
ble but sometimes problematic. Alternatives with other routes of administration 
must be evaluated and giving anti-asthma medication based on symptoms 
would have the best compliance. 
• effectivity of inhaled sodium cromoglycate could not be demonstrated in 
young children with moderate asthma; the value of cromoglycate seems to 
have been exaggerated in previous years and by previous guidelines. 
• validation of asthma symptom scores in all age groups, but especially in chil-
dren under the age of four, is required against disability and symptom percep-
tion as well as against objective lung function measures. 
• general practice can be an excellent setting for prospective research, even for 
large randomised placebo-controlled trials, and use of computerised methods 
improves its applicability and feasibility. 
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Summary 
chapter One 
Introduction 
Respiratory diseases are a major cause of morbidity in children under the age of 
four years and reported prevalences of asthma and wheezing range from 10%-
20%. In treating and investigating young children with asthma, physicians face 
many uncertainties regarding diagnosis, treatment and prognosis. Because objec-
tive measures of asthma are lacking, diagnosis and treatment are based on sub-
jective measures like parental report of symptoms and physical examination. In 
children with asthma, symptoms, specific relief and/or prophylactic anti-asthma 
medication can be indicated, in preschool children preferably administered by 
inhalation with a metered dose inhaler and a spacer devices with face-mask. A 
drug recommended as first-line prophylactic is sodium cromoglycate, a well-
known anti-inflammatory drug and without serious side effects. Treatment with 
inhaled steroids is increasingly used in moderate asthma, at the expense of cro-
moglycate. Inhaled steroids have shown effectivity, also in young children, but 
the long-term safety in young children remains to be established. Therefore, a 
potential role for cromoglycate in treating moderate asthma in young children 
still exists. Information on the effectivity of cromoglycate in young children with 
moderate asthma is lacking. Whether long-term prophylactic treatment is feasible 
in the home situation is unknown, patient and parent adherence and compliance 
have hardly been investigated. 
The main aims of this thesis were to investigate the feasibility of prophylactic in-
halation therapy with a spacer device and facemask in young children with mod-
erate asthma in a general practice setting and to investigate the effectivity of so-
dium cromoglycate. Furthermore, characteristics of children who still used pro-
phylactic inhalation treatment eight months after finishing the trial were studied. 
The execution of this type of clinical trial in general practice has also been criti-
cally evaluated. 
chapter two 
Identifying children with asthma in GP files 
The aim of this first study was to find out whether children with asthma could be 
identified in the files of general practitioners (GP). Parents of all 464 children, 1-4 
years of age, registered in five general practices received a mail questionnaire, 
asking about asthma symptoms experienced by the child, and past and present 
asthma medication. Using the answers, we classified the children as having no, 
mild, moderate or severe asthma according to current guidelines. The GPs' rec-
ords were also checked, for recordings of asthma symptoms, specific asthma 
medication and asthma-related diagnoses. The presence of these items on GPs' 
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records was compared to asthma severity, as derived from the questionnaire an-
swers. The questionnaire was filled in for 87% of the children. 
All children with severe asthma were known to their GPs. The proportion of 
asthmatic children known to their GPs fell with decreasing severity of the disor-
der. Asthma symptoms and specific asthma medication were registered in medi-
cal records more often than asthma-related diagnoses. For all classes of severity 
combined, 75% of preschool children with asthma are known to their GPs. In the 
GPs' files, registered medication turned out to be the best way to identify chil-
dren with asthma. 
chapter three 
Randomised controlled trial of sodium 
cromoglycate 
The feasibility and effects of sodium cromoglycate inhalation therapy were stud-
ied in 218 children, aged 1-4 years with moderate asthma. They were recruited 
through 151 general practitioners between March 1995, and March 1996. They 
were randomly assigned sodium cromoglycate (10 mg three times daily) or pla-
cebo given by inhaler with spacer device and facemask (Aerochamber®) for 5 
months. Rescue medication (ipratropium+fenoterol aerosol) was available during 
the baseline period of 1 month and during the intervention period. Parents com-
pleted a daily symptom-score list during six months. The primary outcome meas-
ure was the proportion of symptom-free days in months 2 to 5. AnalysiS was by 
both intention to treat and on treatment. A total of 167 (77%) children com-
pleted the trial; 131 (78%) of these used at least 80% of the recommended dose. 
Of the children who stopped prematurely, 23 had difficulties with inhaled treat-
ment. The mean proportion of symptom-free days for both groups was greater 
for the treatment period than for the baseline period (95% CI for mean differ-
ence 5.1 to 17.5 cromoglycate, 11.9 to 23.3 placebo). However, there were no 
differences between the sodium cromoglycate and placebo group in the propor-
tion of symptom-free days (mean 65.7 [50 25.31 vs. 64.3 [24.51%; 95% CI for 
difference -8.46 to 5.70) or in any other outcome measure. Our study in a gen-
eral practice setting shows that inhalation therapy with a spacer device and 
facemask is feasible in a majority of children below the age of four years. How-
ever, long-term prophylactic therapy with inhaled sodium cromoglycate is not 
more effective than placebo in this age group. 
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chapter four 
Conducting a clinical trial in general practice 
The practical aspects of conducting the randomised clinical trial in primary care 
are described and the discrepancies between planning and reality are addressed. 
By taking over most time-consuming activities, such as recruitment, randomisa-
tion and follow-up we were able to avoid the pitfalls of research in general prac-
tice: unsuccessful recruitment and withdrawal of GPs and/or patients. We en-
rolled patients from computerised medical records of the GPs based on data on 
prevalent illness. Direct contact with all eligible patients and their caregivers en-
abled us to provide uniform documentation on the difference between eligible 
and enrolled patients. 
chapter five 
Feasibility of prophylactic inhalation therapy 
The purpose of this study was to further investigate the feasibility of and the 
compliance with long-term prophylactic inhalation therapy in children aged 1-4 
years with moderate asthma. Outcome measures for feasibility were willingness 
to participate in the trial, loss of participants during the trial, and compliance. 
Compliance was assessed by weighing the canisters and by means of parental 
daily reports. Of all invited parents (n=449) one third refused to participate in the 
trial due to expected feasibility problems. A total of 232 children started the 
baseline period and 167 children completed the trial; of this latter group 78% 
used 80% or more of the prescribed medication. No difference in drug use was 
found between the cromoglycate and the placebo group. Compared to the 
weight loss of the canisters the parents underreported medication use. There was 
a relationship between the number of symptoms and the compliance on the 
same day. Presence of eczema Was a predictor for better compliance. During the 
trial 51 children dropped out prematurely, 30 of these because of feasibility 
problems. Predictors for these withdrawals were younger age of the child and 
lower education level of the mother. Long-term inhalation therapy with spacer 
device and facemask is feasible in children aged 1-4 years and compliance can 
be relatively high in a selected and well-supported group. Physicians should be 
aware that a considerable proportion of parents of preschool children with mod-
erate asthma are reluctant to start, or will discontinue, long-term prophylactic 
inhalation therapy. 
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chapter six 
Follow-up of the children 
This study investigates whether characteristics of children still using inhaled pro-
phylactic therapy (sodium cromoglycate or steroids) at follow-up, can be found. 
A total of 208 children classified as having moderate asthma were contacted 14 
months after they started the previously described clinical trial, eight months after 
finishing the trial. Patient characteristics from history taking at the start of the trial 
and morbidity characteristics from parental reports during the trial were analysed 
and predictors for long-term use of inhaled prophylaxis were found: perception 
of exercise as a precipitant for respiratory symptoms, sibling(s) with asthmatic 
symptoms, a maternal history of asthma, less attendance at day-care, more fre-
quent and longer episodes with respiratory symptoms and more GP consulta-
tions for respiratory reasons. Characteristics of preschool children still using in-
haled asthma prophylaxis after one year correspond with characteristics for per-
sisting asthrna as found in long-term follow-up studies. 
chapter seven 
Systematic review of sodium cromoglycate 
We systematically reviewed all published randomised placebo-controlled trials on 
prophylactic treatment with sodiurn cromoglycate in children with asthrna. Ran-
domised placebo-controlled trials were identified by means of Medline, Embase, 
the Cochrane Controlled Trial Register, and by selecting references from relevant 
articles. The database of the pharmaceutical company producing sodiurn cromo-
glycate was also consulted. The methodological quality of the studies was as-
sessed by the scoring method of Chalrners. The 95% confidence intervals of dif-
ferences in symptom score between placebo and sodium cromoglycate treat-
rnent were computed. The 95% estimates were pooled and tested for homoge-
neity; in order to explain heterogeneity we evaluated the influence of study char-
acteristics on the outcome and made a funnel plot. A total of 22 randomised pla-
cebo-controlled trials were identified in which methodological scores ranged 
from 24%-79% of the maximum attainable total. The major shortcomings of the 
studies were in "selection and inclusion", II compliance" and II analysis", Statistical 
pooling of 95% confidence intervals was possible for mean difference in symp-
tom scores in 20 studies, and for mean relative improvement in 19 studies. The 
null-hypothesis of homogeneity was rejected. Year of publication of the study 
was a determinant of a positive study result, which means that older studies con-
cluded more often in favour of cromoglycate. For heterogeneity, the overall tol-
erance interval included zero, thus it can not be concluded that sodium cromo-
glycate is superior to placebo. These findings support the decision of guidelines 
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committees to withdraw the recommendation of sodium cromoglycate as the 
first choice for inhaled prophylactic asthma treatment in children, 
chapter eight 
General discussion 
We conclude that inhalation therapy with a spacer device and facemask is feasi-
ble, and compliance can be relatively high, even in a long-term trial with a three 
times daily regimen and a drug that proved to be not more effective than place-
bo, On the other hand, the parents in the study were selected and well moti-
vated, A considerable proportion of young children need effective anti-asthma 
drugs that can be administered in a different way, The randomised placebo-con-
trolled trial was successfully conducted in general practice, as the most appropri-
ate setting for investigating inhalation therapy in young children with moderate 
asthma, due to a study design that minimised the workload for participating gen-
eral practitioners. Increasing computerisation, information and communication 
technology makes medical research in the home situation more accessible and 
feasible, Neither the trial results nor the systematic review of all published place-
bo-controlled trials on inhaled sodium cromoglycate treatment in children with 
asthma, showed an overall beneficial effect of the drug, Therefore, this thesis 
provides additional evidence for national and international guidelines to with-
draw the recommendation of sodium cromoglycate as the first choice in first-line 
inhaled prophylactic treatment. Long-term prophylactic inhalation therapy with 
cromoglycate shows no clinically relevant benefit in young children with asthma, 
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Samenvatting 
hoofdstuk een 
Inleiding 
Aandoeningen van de luchtwegen zijn het meest voorkomende gezondheids-
probleem bij jonge kinderen; astma is de meest voorkomende chronische 
aandoening. Onder de leeftijd van vier jaar wordt, gebaseerd op het symptoom, 
vaak gesproken van 'wheeze', Gerapparteerde prevalenties van astma en 
wheeze varieren van 10% tot 20%, 
Bij het behandelen en het bestuderen van jonge kinderen met astma 
ondervinden artsen een aantal onzekerheden ten aanzien van de diagnose, 
behandeling en prognose. Omdat objectieve uitkomstmaten van astma vrijwel 
ontbreken, worden de diagnose en de behandeling gebaseerd op meer 
subjectieve maten, zoals de door de ouders waargenomen symptomen en het 
lichamelijk onderzoek. Voor kinderen met astmasymptomen kan specifieke 
symptomatische en/of profylactische anti-astmamedicatie ge"lndiceerd zijn; voor 
jonge kinderen bij voorkeur toegediend met een dosis aerosol (spuitbusje) met 
behulp van een voorzetkamer met gezichtsmasker. 
Cromoglycaat is een ontstekingsremmend medicament zander ernstige bijwer-
kingen, geadviseerd als een middel van eerste keuze ter voorkoming van aan-
vallen (zgn profylacticum). In plaats van cromoglycaat wordt behandeling met 
inhalatiesteroYden ter profylaxe van astma meer en meer geadviseerd en 
toegepast. Inhalatiestero"lden hebben bewezen efiectiviteit, ook bij jonge kin-
deren, maar de veiligheid op langere termijn is nog niet geheel duidelijk. Daarom 
zou er nog steeds een rol voor cromoglycaat bij de behandeling van jonge kin-
deren met astma kunnen bestaan. De efiectiviteit van cromoglycaat bij kinderen 
van 0-4 jaar met matig ernstig aslma is onbekend. Of langetermijn profylactische 
behandeling haalbaar is in de thuissituatie en hoe de therapietrouw is, is vrijwel 
niet anderzocht. 
Onderzoek naar de haalbaarheid van profylactische inhalatie-therapie via een 
voorzetkamer met gezichtsmasker bij jonge kinderen met matig ernstig astma in 
een eerstelijns setting alsmede het onderzoeken van de efiectiviteit van cro-
moglycaat zijn de doelstellingen van dit proefschrift. Verder worden kenmerken 
van kinderen die acht maanden na het onderzoek nog profylactische inhalatie-
therapie gebruiken onderzocht. Het uitvoeren van een vergelijkend geneesmid-
delenonderzoek (een zogenaamde trial) in huisartsenpraktijken wordt geeva-
lueerd. 
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hoofdstuk twee 
Het identificeren van kinderen met astma uit 
huisartsenregistraties 
Het doel van deze eerste studie was uit te vinden 01 kinderen met astma konden 
worden g"identiliceerd in de registraties van huisartsen. De ouders van aile 1- tot 
4-jarige kinderen (n~464) uit vijl huisartsenpraktijken ontvingen per post een 
vragenlijst over eventuele astmasymptomen van hun kind, en eventuele astma-
medicatie nu of in het veri eden. Met de antwoorden op deze vragen werden de 
kinderen, in overeenstemming met astmarichtlijnen, geclassiliceerd als hebbende 
geen, mild, matig ernstig of ernstig astma. Daarnaast werden de dossiers van de 
huisartsen bekeken op geregistreerde astmasymptomen, specifieke astma-
medicatie en aan astma gerelateerde diagnosen. Het aanwezig zijn van deze 
items in de huisartsendossiers werd vergeleken met ernst van het astma, zoals 
gebaseerd op de antwoorden op de vragenlijsten. 
De vragenlijst werd ingevuld door de ouders van 87% van de kinderen. Aile 
kinderen met ernstig astma bleken als zodanig bekend bij hun huisarts. De 
proportie kinderen, bekend bij hun huisarts, nam al met de ernst van het astma. 
Astmasymptomen en specifieke astmarnedicatie werden meer in de medische 
dossiers geregistreerd dan astmagerelateerde diagnosen. De huisarts was bekend 
rnet 75% van aile kinderen met astma gebaseerd op de vragenlijst (aile klassen 
van astrna te sam en). Het zoeken op medicatie, geregistreerd door de huisarts in 
het patientendossier, bleek de beste manier om kinderen met astrna te identi-
ficeren. 
hoofdsluk drie 
fen gerandomiseerde, dubbelblinde, placebo-
gecontroleerde trial met cromoglycaat 
We bestudeerden de haalbaarheid en eifectiviteit van inhalatietherapie met 
cromoglycaat in 218 1- tot 4-jarige kinderen met rnatig ernstig astrna. Zij waren 
geselecteerd uit de praktijken van 151 huisartsen tussen maart 1995 en maart 
1996. Het toeval bepaalde of zij cromoglycaat (3maal daags lOmg), hetzij 
placebo kregen/ beide in dosis aerosolen en toegediend via een voorzetkamer 
met gezichtsrnasker (Aerochamber®). Voor situaties van benauwdheid van hun 
kind kregen de ouders noodmedicatie (ipratropiurn+lenoterol aerosol) ter 
beschikking tijdens de baseline periode van een maand en tijdens de 
interventieperiode van vijf maanden. De ouders hielden gedurende deze zes 
maanden dagelijks een symptoomscorelijst bij. De prirnaire uitkomstmaat was de 
proportie symptoornvrije dagen in maand 2-5 van de interventieperiode. 167 
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(77%) kinderen gebruikten gedurende de hele interventieperiode de onderzoeks-
medicatie; 131 (78%) van hen gebruikte meer dan 80% van de voorgeschreven 
dosis. Van de kinderen die voortijdig stop ten, hadden 23 problemen met de 
inhalatietherapie. De gemiddelde proportie symptoomvrije dagen van zowel de 
cromoglycaat- als de placebogroep was hoger tijdens de behandelperiode dan in 
de baseline periode. Er waren echter geen verschillen tussen de beide groepen in 
proportie symptoornvrije dagen, noch in enige andere uitkornstmaat. Onze 
studie in de huisartsensetting laat zien dat inhalatietherapie met een voor-
zetkamer haalbaar is bij de rneerderheid van de kinderen onder de leeftijd van 
vier jaar. Echter, langetermijn profylactische behandeling met ge"'nhaleerd 
cromoglycaat is niet effectiever dan behandeling met placebo bij deze kinderen. 
hoofdsluk vier 
Het uitvoeren van een trial in de 
huisartsenpraktijk 
In dit hoofdstuk worden de praktische aspecten van het uitvoeren van een trial in 
de eerste lijn beschreven en worden discrepanties tussen planning en realiteit 
geevalueerd. Omdat we tijdrovende, met het onderzoek samenhangende 
activiteiten zoals selectie van de kinderen, randornisatie en follow-up, van de 
huisarts overnamen, omzeilden we de valkuilen van onderzoek in de huis-
artsenpraktijk, namelijk tegenvallende patientenwerving en het terugtrekken van 
huisartsen en patienten tijdens het onderzoek. We selecteerden de kinderen 
door in de gecomputeriseerde patientendossiers te zoe ken op gegevens over 
prevalente gezondheidsproblemen, namelijk astma en wheeze. Het directe 
contact van de onderzoekers met de ouders van aile geselecteerde kinderen 
maakt het mogelijk een goed beeld te krijgen van het traject van selectie naar 
deelnarne aan de trial en succesvolle voltooiing van de studie. 
hoofdsluk vijf 
Haalbaarheid van inhalatietherapie 
Het doe I van deze stu die was de haalbaarheid en de therapietrouw met lang-
durige profylactische inhalatietherapie bij 1- tot 4-jarige kinderen met matig 
emstig astma verder te bestuderen. Uitkomstrnaten voor haalbaarheid waren 
mate van bereidheid om deel te nemen aan de trial, uitval van deelnemers 
gedurende de trial en de therapietrouw. Deze laatste werd bepaald door het 
gewicht van de medicijnbusjes (canisters) en door de notitie van de ouders op de 
dagelijkse scorelijst. Van aile ouders die uitgenodigd Waren mee te do en aan de 
trial (n~449) weigerden er 72, omdat zij op voorhand problemen met het inhale-
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ren verwachtten. 232 kinderen startten de baseline periode van de trial en 167 
van hen bleven gedurende de hele trialperiode de onderzoeksmedicatie gebrui-
ken. 78% van hen gebruikte meer dan 80% van de voorgeschreven dosis. 
We vonden geen verschil tussen het medicatiegebruik in de cromoglycaatgroep 
en de placebogroep. Verge Ie ken met het gewichtsverlies van de canisters was er 
sprake van onderrapportage van het medicatiegebruik door de ouders. Het aan-
tal gerapporteerde symptomen op een dag toonde een positief verband met het 
(profylactisch) medicatiegebruik. Bij kinderen met eczeem was sprake van een 
betere therapietrouw. Dertig van de 51 kinderen die voortijdig met de onder-
zoeksmedicatie stopten, deden dat vanwege haalbaarheidsproblemen. Deze 
kinderen waren jonger en hun moeder had gemiddeld een lager opleidings-
niveau. 
Samengevat blijkt langetermijn inhalatietherapie met een voorzetkamer met 
gezichtsmasker haalbaar voor 1- tot 4-jarige kinderen en de therapietrouw is rela-
tief hoog in deze geselecteerde en goed begeleide groep. Een aanzienlijk deel 
van de ouders van jonge kinderen met matig ernstig astma zal echter opzien 
tegen starten of stoppen met de inhalatietherapie. 
hoofdstuk zes 
Follow-up 
Het doel van deze studie was na te gaan of de kinderen die 8 maanden na het 
stoppen van de trial nog profylactische inhalatietherapie gebruiken, zich onder-
scheiden van de kinderen die geen profylactische astmamedicatie meer inha-
leren. In totaal werden de ouders van 208 kinderen met matig ernstig astma 
ondervraagd, 14 maanden nadat zij de trial startten en 8 maanden na het beein-
digen ervan. Patientengegevens, verkregen bij de anamnese aan het begin van 
de trial en gegevens uit de dagelijkse symptoomscorelijsten en de maandelijkse 
interviews gedurende de trial, werden geanalyseerd. De volgende kenmerken 
bleken samen te hangen met aanhoudend gebruik van profylactische inhalatie-
medicatie: inspanning als uitlokker van luchtwegsymptomen, broers/zussen met 
astma, een moeder met astma, minder dagopvang, frequentere en langere epi-
soden met luchtwegsymptomen en meer huisartsbezoeken in verband met 
luchtwegklachten. Deze kenmerken komen overeen met voorspellers van aan-
houdende astma zoals beschreven in langetermijn follow-up studies. 
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hoofdstuk zeven 
Systematische review van cromoglycaat 
Doel van deze stu die was een overzicht op te stellen van aile goed uitgevoerde 
studies met cromoglycaat als (Iangetermijn) profylactische behandeling van 
kinderen met astma. Aile gepubliceerde gerandomiseerde placebogecontro-
leerde trials werden opgespoord en bestudeerd. De studies werden ge'identi-
ficeerd door middel van Medline, Embase, het Cochrane Controlled Trial Register 
en referenties van reeds gevonden artikelen. Ook werd de database van de 
farmaceutische industrie die cromoglycaat vervaardigt geconsulteerd. De metho-
dologische kwaliteit van de studies werd bepaald aan de hand van de scorelijst 
van Chalmers en de verschillen in symptoomscores tussen placebo- en cromogly-
caatbehandeling werden berekend. De uitkomsten van de verschillende studies 
werden samengenomen en getest op homogeniteit; we evalueerden de invloed 
van studiekenmerken op de uitkomst om de heterogeniteit te verklaren en 
maakten een zogenaamde funnel plot. De methodologische scores van de 22 
gevonden trials varieerden van 24% tot 79% van de maximaal te verkrijgen 
score, De grootste tekortkomingen werden gevonden voor de onderdelen 
'selectie en inclusie', 'compliantie' en 'analyse', Samennemen van de resultaten 
was mogelijk voor 20 studies. De nul hypothese van homogeniteit werd verwor-
pen. Het jaar van publicatie bleek een determinant van een positief studie-
resultaat; oudere studies gaven een groter effect van cromoglycaat te zien. In 
verband met de heterogeniteit berekenden wij een tolerantie-interval. Deze 
bleek de nulwaarde te omvatten, zodat we niet kunnen concluderen dat cromo-
glycaat effectiever is dan placebo. 
hoofdstuk acht 
Discussie 
We concluderen dat inhalatietherapie met een voorzetkamer met gezichts-
masker haalbaar is voor 1- tot 4-jarige kinderen met astma en dat de thera-
pietrouw relatief hoog kan zijn, zelfs in een langdurige trial met een driemaal 
daagse dosering en een medicament dat niet effectiever bleek te zijn dan 
placebobehandeling. Opgemerkt moet worden dat de ouders en kinderen in de 
studie geselecteerd en goed gemotiveerd waren. Een aanzienlijk deel van de 
jonge kinderen zou beter uitkomen met effectieve anti-astmamedicamenten die 
niet per inhalatie toegediend hoeven worden. De gerandomiseerde trial werd 
succesvol uitgevoerd in de eerste lijn - de juiste omgeving om inhalatie-therapie 
in jonge kinderen met matig ernstig astma te onderzoeken - door een studie-
design dat de werkbelasting voor de participerende huisartsen beperkt hield. 
Toenemende computerisatie, informatie- en communicatietechnologie maken 
onderzoek in de thuissituatie toegankelijker. De trialresultaten noch de bevin-
109 
SamenvaWng 
dingen van de systematisehe review van aile gepublieeerde plaeebogecon-
troleerde trials over inhalatie met cromoglycaat voor kinderen met astma, lieten 
een positief effeet van het middel zien. Daarmee ondersteunen de bevindingen 
uit dit praefsehrift de terugtrekking van het advies met betrekking tot eramo-
glyeaat als therapie van eerste keus voor de profylaxe van astmasymptomen bij 
kinderen. 
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Het belangrijkste onderdeel van mijn promotie-onderzoek is de trial. Ik wil dan 
oak all ere erst aile kinderen en hun ouders heel hartelijk danken voor hun, vaak 
enthousiaste, deelname. Het is uiteindelijk niet niets am een half jaar lang drie-
maal daags met je peuter te inhaleren, symptoomscorelijsten in te vullen en 
regelmatig onderzoekers thuis te ontvangen. 
Honderdeenenvijftig huisartsen stelden hun praktijk voor ons 'open' am de kin-
deren met astma te rekruteren en te vervolgen. Marjon van Huuksloot en Nel de 
jonge hebben honderden huisbezoeken gedaan en op de meest gekke plaatsen 
moeders opgespoord am niet aan 'lost to follow-up' toe te geven. Het was een 
plezier om met hen samen te werken. 
Naast mijn promotor Prof.dr johan de jongste, bestond de vaste begeleidings-
groep van de trial uit Hans van der Wouden, Lisette van Suijlekom-Smit en Ben 
Ponsioen. johan de jongste wil ik heel hartelijk danken voor het inhoudelijk 
sturen van het project; eerst de trial en later het proefschrift. Toen johan 
hoogleraar werd, zongen zijn collegae van de de afdeling kinderiongziekten een 
lied over de commentaren van zijn hand, meestal geschreven met de vulpen. Ik 
had toen geen idee wat dit betekende, nu weI. Opvallend was niet de kwantiteit 
van het commentaar maar de opbouwende kwaliteit en helderheid ervan. Oak 
de samenvattende opmerkingen als "OK", "Ieuk voor een huisartsenblad", lite 
wordy", "niet goed" of lip rima stuk" waren volledig dUidelijk. 
Hans van der Wouden was als coordinator kinderlijn de begeleider van de 
dagelijkse lopende zaken. Zowel de samenwerking als de zaken liepen prima, 
vooral door zijn humor, bereikbaarheid, zijn altijd open deur en snelheid van 
werken. Sam en met Lisette, de kinderarts van de originele ideeen en praktische 
zaken, gingen we naar een congres in Tours waaraan ik goede herinneringen 
heb. Met Ben Ponsioen deelde ik de kamer op het instituut en hij was altijd druk, 
ge-'-nteresseerd en enthousiast. Later deelde Roos Bernsen oak die karner, schreef 
rnee aan vrijwel aile hoofdstukken en tekent voor de statistiek. Ongelooflijk hoe 
zij wildwest-ideeen in een rnodel kan gieten, analyseren, antwoorden geeft en 
dat allemaal oak nag duidelijk kan uitleggen. 
Sita Biema-Zeinstra, mijn buurvrouw aan de overkant en promovendus in de-
zelfde fase, wil ik bedanken voor de bewaking van ons beider promotieproces. 
Ais zij niet een half jaar voor de einddatum tegen mij had gezegd; 'je moet alles 
wat je klaar hebt eens in een rnap doen, dan lijkt het al wat..:, dan was het 
boekje nu nag niet af. Bovenal wil ik Roos en Sita bedanken voor de vriendschap 
en gezelligheid; die gaan hopelijk door. 
Siep Thomas werd in 1997 hoogleraar huisartsgeneeskunde in Rotterdam en in 
een later stadium promotor van dit project. Hij promootte vooral duidelijkheid, 
opbouw en de rode draad. 
Aile mede-onderzoekers van het huisartsinstituut wi! ik bedanken voor de hulp, 
interesse en vooral voor de goede werksfeer. Oat geldt trouwens oak voor aile 
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andere medewerkers van het instituut, zeker die van het secretariaat. Speciaal 
Pien Schubert en later Trudy van de Pol hebben veel voor de studie gedaan, Met 
veel genoegen kijk ik op de afgelopen vier jaar terug en ik kan me niet heugen 
met tegenzin te hebben gewerkt. 
De grondlegger van het trialprotocol is Hans Uijen; dat gebeurde v66r mijn tijd 
aan het instituut, maar enkele jaren later werd het meeschrijven aan de review 
een deel van zijn huisartsopleiding, Hoewel het schrijven van reviews onder-
zoekers erg somber kan maken, was dit bij ons niet het geval. We hebben erg 
vee I gelachen en ik kan me geen onderwerp bedenken dat we niet hebben 
gereviewd, 
Het Astmafonds financierde de hoofdstudie, Fisons (later Rh6ne-Poulenc Rorer) 
leverde de onderzoeksmedicatie en Boeringer Ingelheim leverden de rescue-
medicatie en de voorzetkamers, Zelfs na de resultaten en conclusies bleef de 
verstandhouding met Fisons plezierig, Het Instituut voor Medische Statistiek wil 
ik noemen omdat zij belangeloos gegevens beschikbaar stelden om inzicht te 
krijgen in voorschrijfcijfers van astma-medicatie. 
Laraine Visser-Isles wi! ik hartelijk bedanken voor de Engelse correcties, Anna 
Bosselaar voor de layout van het proefschrift en Iris de jong voor het omslag-
ontwerp, 
Van het thuisfrant wi! ik allereerst Henk Wi!lem bedanken voor zijn liefdevolle 
support en de continue bereidheid om kruizen te zetten in zijn agenda, En 
eigenlijk 66k allereerst wil ik joke jansen-Kerklaan bedanken voor deze co-
productie, AI jaren is zij oppas voor de kinderen en steunpilaar van ons gezin, 
Het is een voorrecht naar het werk te gaan in de wetenschap dat het thuis 
gezellig is en dat alles 'als vanzelf' doordraait. Mijn moeder en schoonouders en 
Truus jongman spelen daarbij een enorm belangrijke ral en hen dank ik voor aile 
liefde, gezelligheid, hulp, opvang en leuke uitjes, 
Beate Walhof, hartsvriendin vanaf klas 1 g, en jan Kees van der Kamp, harts-
zwager van de late telefoongesprekken, waren meteen be reid paranimf te zijn 
(Beate liet zelfs 'Mexico' lopen), Ik vind het heel bijzonder met hen 'te staan', 
Andere vrienden en familie toonden altijd interesse en speciaal mijn braers dank 
ik voor hun gezonde onbegrip en goede, niet-wetenschappelijke adviezen, 
Goof, Wietske en Thijs dank ik voor de tekeningen op het omslag en voor het 
feit dat zij steeds weer duidelijk maken dat waar het werkelijk om gaat meestal 
niet in boekjes staat. 
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